

CORRECTED
VERSION*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|--|---|
| <p>(51) International Patent Classification⁶ : A61K 38/00, 48/00, C07H 21/02, 21/04, C07K 14/00, C12N 1/20, 15/00, 15/11, 15/63, 15/85, 15/86</p> | <p>A1</p> | <p>(11) International Publication Number: WO 98/42362 (43) International Publication Date: 1 October 1998 (01.10.98)</p> |
| <p>(21) International Application Number: PCT/US98/06208 (22) International Filing Date: 27 March 1998 (27.03.98) (30) Priority Data: 08/828,010 27 March 1997 (27.03.97) US (71) Applicants: MILLENNIUM PHARMACEUTICALS, INC. [US/US]; 640 Memorial Drive, Cambridge, MA 02139 (US). THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 300 Lakeside Drive, Oakland, CA 94612 (US). (72) Inventors: CHEN, Hong; 46 Aspinwal Avenue #2, Brookline, MA 02146 (US). FREIMER, Nelson, B.; 630 29th Street, San Francisco, CA 94131 (US). (74) Agents: CORUZZI, Laura, A, et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).</p> | <p>(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i></p> | |
| <p>(54) Title: METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS</p> | | |
| <p>(57) Abstract</p> | | |
| <p>The present invention relates to the mammalian <i>fsH05</i> gene, a novel gene associated with bipolar affective disorder (BAD) in humans. The invention encompasses <i>fsH05</i> nucleic acids, recombinant DNA molecules, cloned genes or degenerate variants thereof, <i>fsH05</i> gene products and antibodies directed against such gene products, cloning vectors containing mammalian <i>fsH05</i> gene molecules, and hosts that have been genetically engineered to express such molecules. The invention further relates to methods for the identification of compounds that modulate the expression of <i>fsH05</i> and to using such compounds as therapeutic agents in the treatment of <i>fsH05</i> disorders and neuropsychiatric disorders. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of <i>fsH05</i> disorders and neuropsychiatric disorders including schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar affective disorder, and to methods and compositions for the treatment of these disorders.</p> | | |

*(Referred to in PCT Gazette No. 09/1999, Section II)

B13

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | YN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

**METHODS AND COMPOSITIONS FOR THE
DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS**

This invention was supported in part by Grant Nos.
5 R03 MH-48695, R01 MH-47563, R01-MH49499, and K21MH00916 from
the National Institutes of Health. The U.S. Government may
have rights in this invention.

1. INTRODUCTION

10 The present invention relates to the mammalian
fsh05 gene, a novel gene associated with neuropsychiatric
disorders in humans. The invention encompasses *fsh05* nucleic
acids, recombinant DNA molecules, cloned genes or degenerate
variants thereof, *fsh05* gene products and antibodies directed
15 against such gene products, cloning vectors containing
mammalian *fsh05* gene molecules, and hosts that have been
genetically engineered to express such molecules. The
invention further relates to methods for the identification
of compounds that modulate the expression, synthesis and
20 activity of *fsh05* and to using compounds such as those
identified as therapeutic agents in the treatment of a *fsh05*
disorder or a neuropsychiatric disorder, including, by way of
example and not of limitation, schizophrenia, attention
deficit disorder, a schizoaffective disorder, a bipolar
25 affective disorder or a unipolar affective disorder. The
invention also relates to methods for the diagnostic
evaluation, genetic testing and prognosis of a *fsh05* disorder
or of a neuropsychiatric disorder, including, by way of
example and not of limitation, schizophrenia, attention
30 deficit disorder, a schizoaffective disorder, a bipolar
affective disorder or a unipolar affective disorder.

2. BACKGROUND OF THE INVENTION

35 There are only a few psychiatric disorders in which
clinical manifestations of the disorder can be correlated
with demonstrable defects in the structure and/or function of
the nervous system. Well-known examples of such disorders

include Huntington's disease, which can be traced to a mutation in a single gene and in which neurons in the striatum degenerate, and Parkinson's disease, in which dopaminergic neurons in the nigro-striatal pathway
5 degenerate. The vast majority of psychiatric disorders, however, presumably involve subtle and/or undetectable changes, at the cellular and/or molecular levels, in nervous system structure and function. This lack of detectable neurological defects distinguishes "neuropsychiatric"
10 disorders, such as schizophrenia, attention deficit disorders, schizoaffective disorder, bipolar affective disorders, or unipolar affective disorder, from neurological disorders, in which anatomical or biochemical pathologies are manifest. Hence, identification of the causative defects and
15 the neuropathologies of neuropsychiatric disorders are needed in order to enable clinicians to evaluate and prescribe appropriate courses of treatment to cure or ameliorate the symptoms of these disorders.

One of the most prevalent and potentially
20 devastating of neuropsychiatric disorders is bipolar affective disorder (BAD), also known as bipolar mood disorder (BP) or manic-depressive illness, which is characterized by episodes of elevated mood (mania) and depression (Goodwin, et al., 1990, *Manic Depressive Illness*, Oxford University Press,
25 New York). The most severe and clinically distinctive forms of BAD are BP-I (severe bipolar affective (mood) disorder), which affects 2-3 million people in the United States, and SAD-M (schizoaffective disorder manic type). They are characterized by at least one full episode of mania, with or
30 without episodes of major depression (defined by lowered mood, or depression, with associated disturbances in rhythmic behaviors such as sleeping, eating, and sexual activity). BP-I often co-segregates in families with more etiologically heterogeneous syndromes, such as with a unipolar affective
35 disorder such as unipolar major depressive disorder (MDD), which is a more broadly defined phenotype (Freimer and Reus, 1992, in *The Molecular and Genetic Basis of Neurological*

Disease, Rosenberg, et al., eds., Butterworths, New York, pp. 951-965; McInnes and Freimer, 1995, *Curr. Opin. Genet. Develop.*, 5, 376-381). BP-I and SAD-M are severe mood disorders that are frequently difficult to distinguish from
5 one another on a cross-sectional basis, follow similar clinical courses, and segregate together in family studies (Rosenthal, et al., 1980, *Arch. General Psychiat.* 37, 804-810; Levinson and Levitt, 1987, *Am. J. Psychiat.* 144, 415-426; Goodwin, et al., 1990, *Manic Depressive Illness*, Oxford
10 University Press, New York). Hence, methods for distinguishing neuropsychiatric disorders such as these are needed in order to effectively diagnose and treat afflicted individuals.

Currently, individuals are typically evaluated for
15 BAD using the criteria set forth in the most current version of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM). While many drugs have been used to treat individuals diagnosed with BAD, including lithium salts, carbamazepine and valproic acid,
20 none of the currently available drugs are adequate. For example, drug treatments are effective in only approximately 60-70% of individuals diagnosed with BP-I. Moreover, it is currently impossible to predict which drug treatments will be effective in, for example, particular BP-I affected
25 individuals. Commonly, upon diagnosis, affected individuals are prescribed one drug after another until one is found to be effective. Early prescription of an effective drug treatment, therefore, is critical for several reasons, including the avoidance of extremely dangerous manic episodes
30 and the risk of progressive deterioration if effective treatments are not found.

The existence of a genetic component for BAD is strongly supported by segregation analyses and twin studies (Bertelson, et al., 1977, *Br. J. Psychiat.* 130, 330-351;
35 Freimer and Reus, 1992, in *The Molecular and Genetic Basis of Neurological Disease*, Rosenberg, et al., eds., Butterworths, New York, pp. 951-965; Pauls, et al., 1992, *Arch. Gen.*

Psychiat. 49, 703-708). Efforts to identify the chromosomal location of genes that might be involved in BP-I, however, have yielded disappointing results in that reports of linkage between BP-I and markers on chromosomes X and 11 could not be
5 independently replicated nor confirmed in the re-analyses of the original pedigrees, indicating that with BAD linkage studies, even extremely high lod scores at a single locus, can be false positives (Baron, et al., 1987, Nature 326, 289-292; Egeland, et al., 1987, Nature 325, 783-787; Kelsoe, et
10 al., 1989, Nature 342, 238-243; Baron, et al., 1993, Nature Genet. 3, 49-55).

Recent investigations have suggested possible localization of BAD genes on chromosomes 18p and 21q, but in both cases the proposed candidate region is not well defined
15 and no unequivocal support exists for either location (Berrettini, et al., 1994, Proc. Natl. Acad. Sci. USA 91, 5918-5921; Murray, et al., 1994, Science 265, 2049-2054; Pauls, et al., 1995, Am. J. Hum. Genet. 57, 636-643; Maier, et al., 1995, Psych. Res. 59, 7-15; Straub, et al., 1994,
20 Nature Genet. 8, 291-296).

Mapping genes for common diseases believed to be caused by multiple genes, such as BAD, may be complicated by the typically imprecise definition of phenotypes, by etiologic heterogeneity, and by uncertainty about the mode of
25 genetic transmission of the disease trait. With neuropsychiatric disorders there is even greater ambiguity in distinguishing individuals who likely carry an affected genotype from those who are genetically unaffected. For example, one can define an affected phenotype for BAD by
30 including one or more of the broad grouping of diagnostic classifications that constitute the mood disorders: BP-I, SAD-M, MDD, and bipolar affective (mood) disorder with hypomania and major depression (BP-II).

Thus, one of the greatest difficulties facing
35 psychiatric geneticists is uncertainty regarding the validity of phenotype designations, since clinical diagnoses are based solely on clinical observation and subjective reports. Also,

with complex traits such as neuropsychiatric disorders, it is difficult to genetically map the trait-causing genes because: (1) neuropsychiatric disorder phenotypes do not exhibit classic Mendelian recessive or dominant inheritance patterns 5 attributable to a single genetic locus, (2) there may be incomplete penetrance, i.e., individuals who inherit a predisposing allele may not manifest disease; (3) a phenocopy phenomenon may occur, i.e., individuals who do not inherit a predisposing allele may nevertheless develop disease due to 10 environmental or random causes; (4) genetic heterogeneity may exist, in which case mutations in any one of several genes may result in identical phenotypes.

Despite these difficulties, however, identification of the chromosomal location, sequence and function of genes 15 and gene products responsible for causing neuropsychiatric disorders such as bipolar affective disorders is of great importance for genetic counseling, diagnosis and treatment of individuals in affected families.

20

3. SUMMARY OF THE INVENTION

It is an object of the present invention to identify genetic bases for neuropsychiatric disorders, provide methods of treating and diagnosing neuropsychiatric disorders, and provide methods for identifying compounds for 25 use as part of therapeutic and/or diagnostic methods.

In particular, the present invention relates, first, to the mammalian *fsh05* gene, a novel gene associated with neuropsychiatric disorders in humans, e.g., schizophrenia, attention deficit disorders, schizoaffective 30 disorders, bipolar affective disorders, and/or unipolar affective disorders, including *fsh05* nucleic acids, recombinant DNA molecules, cloned genes or degenerate variants thereof.

The invention further relates to novel mammalian 35 *fsh05* gene products and to antibodies directed against such mammalian *fsh05* gene products, or conserved variants or fragments thereof. *fsh05* nucleic acid and amino acid

sequences are provided herein. The invention also relates to vectors, including expression vectors, containing mammalian *fsh05* gene molecules, and hosts that have been genetically engineered to express such *fsh05* gene products.

5 The invention further relates to methods for the treatment of *fsh05* or neuropsychiatric disorders, wherein such methods comprise administering compounds which modulate the expression of a mammalian *fsh05* gene and/or the synthesis or activity of a mammalian *fsh05* gene product so symptoms of
10 the disorder are ameliorated.

 The invention further relates to methods for the treatment of mammalian *fsh05* or neuropsychiatric disorders resulting from *fsh05* gene mutations, wherein such methods comprise supplying the mammal with a nucleic acid molecule
15 encoding an unimpaired *fsh05* gene product such that an unimpaired *fsh05* gene product is expressed and symptoms of the disorder are ameliorated.

 The invention further relates to methods for the treatment of mammalian *fsh05* or neuropsychiatric disorders
20 resulting from *fsh05* gene mutations, wherein such methods comprise supplying the mammal with a cell comprising a nucleic acid molecule that encodes an unimpaired *fsh05* gene product such that the cell expresses the unimpaired *fsh05* gene product and symptoms of the disorder are ameliorated.

25 In addition, the present invention is directed to methods that utilize the *fsh05* gene and/or gene product sequences for the diagnostic evaluation, genetic testing and prognosis of a *fsh05* disorder or a neuropsychiatric disorder. For example, the invention relates to methods for diagnosing
30 *fsh05* or neuropsychiatric disorders, wherein such methods comprise measuring *fsh05* gene expression in a patient sample, or detecting a *fsh05* mutation in the genome of the mammal suspected of exhibiting such a disorder.

 The invention still further relates to methods for
35 identifying compounds capable of modulate the expression of the mammalian *fsh05* gene and/or the synthesis or activity of the mammalian *fsh05* gene products, wherein such methods

comprise contacting a compound to a cell that expresses a *fsh05* gene, measuring the level of *fsh05* gene expression, gene product expression or gene product activity, and comparing this level to the level of *fsh05* gene expression, 5 gene product expression or gene product activity produced by the cell in the absence of the compound, such that if the level obtained in the presence of the compound differs from that obtained in its absence, a compound capable of modulating the expression of the mammalian *fsh05* gene and/or 10 the synthesis or activity of the mammalian *fsh05* gene products has been identified.

fsh05 gene and/or gene products can also be utilized as markers for mapping of the region of the long arm of human chromosome 18 spanned by chromosomal markers 15 D18S1121 and DS18S380.

The neuropsychiatric disorders referred to herein can include, but are not limited to, schizophrenia; attention deficit disorder; a schizoaffective disorder; a bipolar affective disorder, e.g., severe bipolar affective (mood) 20 disorder (BP-I), bipolar affective (mood) disorder with hypomania and major depression (BP-II); schizoaffective disorder manic type (SAD-M); or a unipolar affective disorder e.g., unipolar major depressive disorder (MDD).

The term "*fsh05* disorder" as used herein refers to 25 a disorder involving an aberrant level of *fsh05* gene expression, gene product synthesis and/or gene product activity relative to levels found in normal, unaffected, unimpaired individuals, levels found in clinically normal individuals, and/or levels found in a population whose level 30 represents a baseline, average *fsh05* level.

3.1. DEFINITIONS

As used herein, the following terms shall have the abbreviations indicated.

35

BAC, bacterial artificial chromosomes

BAD, bipolar affective disorder(s)

BP, bipolar mood disorder
BP-I, severe bipolar affective (mood) disorder
BP-II, bipolar affective (mood) disorder with
hypomania and major depression

5

bp, base pair(s)
EST, expressed sequence tag
lod, logarithm of odds
MDD, unipolar major depressive disorder

10

RT-PCR, reverse transcriptase PCR
SSCP, single-stranded conformational polymorphism
SAD-M, schizoaffective disorder manic type
STS, short tag sequence
YAC, yeast artificial chromosome

15

4. BRIEF DESCRIPTION OF THE FIGURES

Figure 1 depicts *fsh05* nucleotide (SEQ ID NO:1) and amino acid sequences (SEQ ID NO:2).

5. DETAILED DESCRIPTION OF THE INVENTION

20

Described herein is the identification of a novel mammalian *fsh05* gene, which is associated with neuropsychiatric disorders such as human bipolar affective disorder (BAD). *fsh05* gene and gene product sequences are described in the example presented below in Section 6. This invention is based, in part, on the genetic and physical mapping of the *fsh05* gene to a specific, narrow portion of chromosome 18, also described in the Example presented below in Section 6.

30

5.1. THE *fsh05* GENE

The *fsh05* gene is a novel gene associated with neuropsychiatric disorders, including BAD. Nucleic acid sequences of the identified *fsh05* gene are described herein. As used herein, "*fsh05* gene" refers to:

35

(a) a nucleic acid molecule containing the DNA sequence shown in Figure 1 (SEQ ID NO:1) or contained in the cDNA clones FSH5-1 (ATCC accession No. 98317) and/or FSH5-2

(ATCC accession No. 98318), as deposited with the American Type Culture Collection (ATCC);

(b) any DNA sequence that encodes a polypeptide containing: the amino acid sequence shown in Figure 1 (SEQ ID NO:2), the amino acid sequence encoded by the cDNA clones FSH5-1 (ATCC 98317) and/or FSH5-2 (ATCC 98318);

(c) any DNA sequence that hybridizes to the complement of the DNA sequences that encode the amino acid sequence shown in Figure 1 (SEQ ID NO:2), or contained in the cDNA clones FSH5-1 (ATCC 98317) and/or FSH5-2 (ATCC 98318), as deposited with the ATCC, under highly stringent conditions, e.g., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel F.M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3); and/or

(d) any DNA sequence that hybridizes to the complement of the DNA sequences that encode the amino acid sequence shown in Figure 1 (SEQ ID NO:2) or contained in the cDNA clones FSH5-1 (ATCC 98317) and/or FSH5-2 (ATCC 98318), as deposited with the ATCC, under less stringent conditions, such as moderately stringent conditions, e.g., washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, supra), and encodes a gene product functionally equivalent to a *fsh05* gene product.

The term "functionally equivalent to a *fsh05* gene product," as used herein, refers to a gene product that exhibits at least one of the biological activities of an endogenous, unimpaired *fsh05* gene. In one embodiment, a functionally equivalent *fsh05* gene product is one that, when present in an appropriate cell type, is capable of ameliorating, preventing or delaying the onset of one or more symptoms of a *fsh05* disorder. In another embodiment, a functionally equivalent *fsh05* gene product is one that, when present in an appropriate cell type, is capable of ameliorating, preventing or delaying the onset of one or more

symptoms of a neuropsychiatric disorder. In yet another embodiment, a functionally equivalent *fsh05* gene product is one that, when present in an appropriate cell type, is capable of ameliorating, preventing or delaying the onset of
5 one or more symptoms of a BAD, such as, for example, severe bipolar affective (mood) disorder, bipolar affective (mood) disorder with hypomania and major depression, or schizoaffective disorder manic type.

fsh05 sequences can include, for example either
10 genomic DNA (gDNA) or cDNA sequences. When referring to a nucleic acid which encodes a given amino acid sequence, therefore, it is to be understood that the nucleic acid need not only be a cDNA molecule, but can also, for example, refer to a gDNA sequence from which an mRNA species is transcribed
15 that is processed to encode the given amino acid sequence.

As used herein, *fsh05* gene may also refer to degenerate variants of DNA sequences (a) through (d).

The invention also includes nucleic acid molecules, preferably DNA molecules, that hybridize to, and are
20 therefore the complements of, the DNA sequences (a) through (d), in the preceding paragraph. Such hybridization conditions may be highly stringent or less highly stringent, as described above. In instances wherein the nucleic acid molecules are deoxyoligonucleotides ("oligos"), highly
25 stringent conditions may refer, e.g., to washing in 6xSSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligos), 48°C (for 17-base oligos), 55°C (for 20-base oligos), and 60°C (for 23-base oligos). These nucleic acid molecules may encode or act as *fsh05* gene antisense
30 molecules, useful, for example, in *fsh05* gene regulation (for and/or as antisense primers in amplification reactions of *fsh05* gene nucleic acid sequences). With respect to *fsh05* gene regulation, such techniques can be used to regulate, for example, a *fsh05* disorder or a neuropsychiatric disorder,
35 such as BAD. Further, such sequences may be used as part of ribozyme and/or triple helix sequences, also useful for *fsh05* gene regulation. Still further, such molecules may be used

as components of diagnostic methods whereby, for example, the presence of a particular *fsh05* allele responsible for causing a *fsh05* disorder or neuropsychiatric disorder such as BAD, e.g., manic-depression, may be detected.

5 The invention also encompasses:

(a) DNA vectors that contain any of the foregoing *fsh05* coding sequences and/or their complements (*i.e.*, antisense);

(b) DNA expression vectors that contain any of the
10 foregoing *fsh05* coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences; and

(c) genetically engineered host cells that contain any of the foregoing *fsh05* coding sequences operatively
15 associated with a regulatory element that directs the expression of the coding sequences in the host cell.

As used herein, regulatory elements include but are not limited to inducible and non-inducible promoters, enhancers, operators and other elements known to those
20 skilled in the art that drive and regulate expression. Such regulatory elements include but are not limited to the cytomegalovirus hCMV immediate early gene, the early or late promoters of SV40 adenovirus, the *lac* system, the *trp* system, the *TAC* system, the *TRC* system, the major operator and
25 promoter regions of phage A, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast α -mating factors.

The invention further includes fragments of any of
30 the DNA sequences disclosed herein.

In one embodiment, the *fsh05* gene sequences of the invention are mammalian gene sequences, with human sequences being preferred.

In another embodiment, the *fsh05* gene sequences of
35 the invention are gene sequences encoding *fsh05* gene products containing polypeptide portions corresponding to (that is, polypeptide portions exhibiting amino acid sequence

similarity to) the amino acid sequence depicted in Figure 1, wherein the corresponding portion exhibits greater than about 50% amino acid identity with the Figure 1 sequence.

In yet another embodiment, the *fsh05* gene sequences of the invention are gene sequences encoding *fsh05* gene products containing polypeptide portions corresponding to (that is, polypeptide portions exhibiting amino acid sequence similarity to) the amino acid sequence depicted in Figure 1, wherein the corresponding portion exhibits greater than about 50% amino acid identity with the Figure 1 sequence, averaged across the *fsh05* gene product's entire length.

In addition to the human *fsh05* gene sequences disclosed in Figure 1, additional *fsh05* gene sequences can be identified and readily isolated, without undue experimentation, by molecular biological techniques well known in the art, used in conjunction with the *fsh05* sequences disclosed herein. For example, additional human *fsh05* gene sequences at the same or at different genetic loci as those disclosed in Figure 1 can be isolated readily. There can exist, for example, genes at other genetic or physical loci within the human genome that encode proteins that have extensive homology to one or more domains of the *fsh05* gene product and that encode gene products functionally equivalent to a *fsh05* gene product. Further, homologous *fsh05* gene sequences present in other species can be identified and isolated readily.

With respect to identification and isolation of *fsh05* gene sequences present at the same genetic or physical locus as those sequences disclosed in Figure 1, such sequences can, for example, be obtained readily by utilizing standard sequencing and bacterial artificial chromosome (BAC) technologies in connection with BAC54 (Identification Reference EpHS996, ATCC Accession No. 98363).

For example, sheared libraries can be made from BAC54. Fragments of a convenient size, e.g., in the size range of approximately 1 kb, are cloned into a standard plasmid, and sequenced. Further *fsh05* sequences can then

readily be identified by alignment of the BAC sequences with the *fsh05* sequences depicted in Figure 1. Alternatively, BAC subclones containing additional *fsh05* sequences can be identified by identifying those subclones which hybridize to 5 probes derived from the *fsh05* sequences depicted in Figure 1.

With respect to the cloning of a *fsh05* gene homologue in human or other species (e.g., mouse), the isolated *fsh05* gene sequences disclosed herein may be labeled and used to screen a cDNA library constructed from mRNA 10 obtained from appropriate cells or tissues (e.g., brain tissues) derived from the organism (e.g., mouse) of interest. The hybridization conditions used should be of a lower stringency when the cDNA library is derived from an organism different from the type of organism from which the labeled 15 sequence was derived.

Alternatively, the labeled fragment may be used to screen a genomic library derived from the organism of interest, again, using appropriately stringent conditions. Low stringency conditions are well known to those of skill in 20 the art, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. For guidance regarding such conditions see, for example, Sambrook, et al., 1989, Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Press, 25 N.Y.; and Ausubel, et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

Further, a *fsh05* gene homologue may be isolated from, for example, human nucleic acid, by performing PCR 30 using two degenerate oligonucleotide primer pools designed on the basis of amino acid sequences within the *fsh05* gene product disclosed herein. The template for the reaction may be cDNA obtained by reverse transcription of mRNA prepared from, for example, human or non-human cell lines or tissue 35 known or suspected to express a *fsh05* gene allele (such as human brain cell lines e.g., ATCC CRL-7605, ATCC CRL-7948, ATCC CRL-2060 PFSK-1, ATCC CRL-2176 SW 598, American Type

Culture Collection, Rockville, MD; cortical neuronal cell lines, e.g., Ronnett, et al., 1990, Science 248, 603-605; Ronnett, et al., 1994, Neuroscience 63, 1081-1099; and Dunn, et al., 1996, Int. J. Dev. Neurosci. 14, 61-68; neuronal line
5 HCN-1A, Westlund et al., 1992, Int. J. Dev. Neurosci. 10, 361-373).

The PCR product may be subcloned and sequenced to ensure that the amplified sequences represent the sequences of a *fsh05* gene nucleic acid sequence. The PCR fragment may
10 then be used to isolate a full length cDNA clone by a variety of methods. For example, the amplified fragment may be labeled and used to screen a bacteriophage cDNA library. Alternatively, the labeled fragment may be used to isolate genomic clones via the screening of a genomic library.

15 PCR technology may also be utilized to isolate full length cDNA sequences. For example, RNA may be isolated, following standard procedures, from an appropriate cellular or tissue source (i.e., one known, or suspected, to express the *fsh05* gene, such as, for example, blood samples or brain
20 tissue samples obtained through biopsy or post-mortem). A reverse transcription reaction may be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid may then be "tailed"
25 with guanines using a standard terminal transferase reaction, the hybrid may be digested with RNAase H, and second strand synthesis may then be primed with a poly-C primer. Thus, cDNA sequences upstream of the amplified fragment may easily be isolated. For a review of cloning strategies that may be
30 used, see e.g., Sambrook et al., 1989, *supra*.

fsh05 gene sequences may additionally be used to isolate mutant *fsh05* gene alleles. Such mutant alleles may be isolated from individuals either known or proposed to have a genotype that contributes to the symptoms of a *fsh05*
35 disorder, or a neuropsychiatric disorder such as BAD, for example, manic-depression. Mutant alleles and mutant allele products may then be utilized in the therapeutic and

diagnostic systems described below. Additionally, such *fsh05* gene sequences can be used to detect *fsh05* gene regulatory (e.g., promoter) defects which can be associated with a *fsh05* disorder, or a neuropsychiatric disorder such as BAD.

5 A cDNA of a mutant *fsh05* gene may be isolated, for example, by using PCR, a technique that is well known to those of skill in the art. In this case, the first cDNA strand may be synthesized by hybridizing an oligo-dT
10 oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual putatively carrying the mutant *fsh05* allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5' end of the normal gene.
15 Using these two primers, the product is then amplified via PCR, cloned into a suitable vector, and subjected to DNA sequence analysis through methods well known to those of skill in the art. By comparing the DNA sequence of the mutant *fsh05* allele to that of the normal *fsh05* allele, the
20 mutation(s) responsible for the loss or alteration of function of the mutant *fsh05* gene product can be ascertained.

Alternatively, a genomic library can be constructed using DNA obtained from an individual suspected of or known to carry a mutant *fsh05* allele, or a cDNA library can be
25 constructed using RNA from a tissue known, or suspected, to express a mutant *fsh05* allele. An unimpaired *fsh05* gene or any suitable fragment thereof may then be labeled and used as a probe to identify the corresponding mutant *fsh05* allele in such libraries. Clones containing the mutant *fsh05* gene
30 sequences may then be purified and subjected to sequence analysis according to methods well known to those of skill in the art.

Additionally, an expression library can be constructed utilizing cDNA synthesized from, for example, RNA
35 isolated from a tissue known, or suspected, to express a mutant *fsh05* allele in an individual suspected of or known to carry such a mutant allele. In this manner, gene products

made by the putatively mutant tissue may be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against the normal *fsh05* gene product, as described, below, in Section 5.3. (For 5 screening techniques, see, for example, Harlow and Lane, eds., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor.)

In cases where a *fsh05* mutation results in an expressed gene product with altered function (e.g., as a 10 result of a missense or a frameshift mutation), a polyclonal set of anti-*fsh05* gene product antibodies are likely to cross-react with the mutant *fsh05* gene product. Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis 15 according to methods well known to those of skill in the art.

fsh05 mutations can further be detected using PCR amplification techniques. Primers can routinely be designed to amplify overlapping regions of the whole *fsh05* sequence including the promoter region. In one embodiment, primers 20 are designed to cover the exon-intron boundaries such that, first, coding regions can be scanned for mutations. Genomic DNA isolated from lymphocytes of normal and affected individuals is used as PCR template. PCR products from normal and affected individuals are compared, either by 25 single strand conformational polymorphism (SSCP) mutation detection techniques and/or by sequencing. The mutations responsible for the loss or alteration of function of the mutant *fsh05* gene product can then be ascertained.

30 5.2. PROTEIN PRODUCTS OF THE *fsh05* GENE

fsh05 gene products, or peptide fragments thereof, can be prepared for a variety of uses. For example, such gene products, or peptide fragments thereof, can be used for the generation of antibodies, in diagnostic assays, or for 35 the identification of other cellular or extracellular gene products involved in the regulation of a *fsh05* disorder, or a neuropsychiatric disorder such as BAD.

The amino acid sequence depicted in Figure 1 (SEQ ID NO:2) represents a *fsh05* gene product. The *fsh05* gene product, sometimes referred to herein as a "*fsh05* protein", includes those gene products encoded by the *fsh05* gene
5 sequences described in Section 5.1, above.

In addition, *fsh05* gene products may include proteins that represent functionally equivalent (see Section 5.1 for a definition) gene products. Such an equivalent *fsh05* gene product may contain deletions, including internal
10 deletions, additions, including additions yielding fusion proteins, or substitutions of amino acid residues within and/or adjacent to the the amino acid sequence encoded by the *fsh05* gene sequences described, above, in Section 5.1, but that result in a "silent" change, in that the change produces
15 a functionally equivalent *fsh05* gene product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine,
20 leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged
25 (acidic) amino acids include aspartic acid and glutamic acid.

Alternatively, where alteration of function is desired, deletion or non-conservative alterations can be engineered to produce altered *fsh05* gene products. Such alterations can, for example, alter one or more of the
30 biological functions of the *fsh05* gene product. Further, such alterations can be selected so as to generate *fsh05* gene products that are better suited for expression, scale up, etc. in the host cells chosen. For example, cysteine residues can be deleted or substituted with another amino
35 acid residue in order to eliminate disulfide bridges.

The *fsh05* gene products, peptide fragments thereof and fusion proteins thereof, may be produced by recombinant

DNA technology using techniques well known in the art. Thus, methods for preparing the *fsh05* gene polypeptides, peptides, fusion peptide and fusion polypeptides of the invention by expressing nucleic acid containing *fsh05* gene sequences are
5 described herein. Methods that are well known to those skilled in the art can be used to construct expression vectors containing *fsh05* gene product coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, *in vitro*
10 recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. See, for example, the techniques described in Sambrook, et al., 1989, *supra*, and Ausubel, et al., 1989, *supra*. Alternatively, RNA capable of encoding *fsh05* gene product sequences may be chemically synthesized
15 using, for example, synthesizers. See, for example, the techniques described in "Oligonucleotide Synthesis", 1984, Gait, ed., IRL Press, Oxford.

A variety of host-expression vector systems may be utilized to express the *fsh05* gene coding sequences of the
20 invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells that may, when transformed or transfected with the appropriate nucleotide coding sequences, exhibit the *fsh05* gene product
25 of the invention *in situ*. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing *fsh05* gene product coding sequences; yeast (e.g., *Saccharomyces*,
30 *Pichia*) transformed with recombinant yeast expression vectors containing the *fsh05* gene product coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the *fsh05* gene product coding sequences; plant cell systems infected with
35 recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti

plasmid) containing *fsh05* gene product coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g.,
5 metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use
10 intended for the *fsh05* gene product being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of *fsh05* protein or for raising antibodies to *fsh05* protein, for example, vectors that direct the expression of high
15 levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 2, 1791), in which the *fsh05* gene product coding sequence may be ligated individually into the vector in frame
20 with the *lac Z* coding region so that a fusion protein is produced; pIN vectors (Inouye and Inouye, 1985, Nucleic Acids Res. 13, 3101-3109; Van Heeke and Schuster, 1989, J. Biol. Chem. 264, 5503-5509); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins
25 with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa
30 protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica*, nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera*
35 *frugiperda* cells. The *fsh05* gene coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of

an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of *fsh05* gene coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the
5 proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect *Spodoptera frugiperda* cells in which the inserted gene is expressed. (e.g., see Smith, et al., 1983, J. Virol. 46, 584; Smith, U.S. Patent No. 4,215,051).

10 In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector; the *fsh05* gene coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late
15 promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing
20 *fsh05* gene product in infected hosts. (e.g., See Logan and Shenk, 1984, Proc. Natl. Acad. Sci. USA 81, 3655-3659). Specific initiation signals may also be required for efficient translation of inserted *fsh05* gene product coding sequences. These signals include the ATG initiation codon
25 and adjacent sequences. In cases where an entire *fsh05* gene, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the *fsh05* gene
30 coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous
35 translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of

appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner, et al., 1987, Methods in Enzymol. 153, 516-544).

In addition, a host cell strain may be chosen that
5 modulates the expression of the inserted sequences, or
modifies and processes the gene product in the specific
fashion desired. Such modifications (e.g., glycosylation)
and processing (e.g., cleavage) of protein products may be
important for the function of the protein. Different host
10 cells have characteristic and specific mechanisms for the
post-translational processing and modification of proteins
and gene products. Appropriate cell lines or host systems
can be chosen to ensure the correct modification and
processing of the foreign protein expressed. To this end,
15 eukaryotic host cells that possess the cellular machinery for
proper processing of the primary transcript, glycosylation,
and phosphorylation of the gene product may be used. Such
mammalian host cells include but are not limited to CHO,
VERO, BHK, HeLa, COS, MDCK, 293, 3T3, and WI38.

20 For long-term, high-yield production of recombinant
proteins, stable expression is preferred. For example, cell
lines that stably express the *fsh05* gene product may be
engineered. Rather than using expression vectors that
contain viral origins of replication, host cells can be
25 transformed with DNA controlled by appropriate expression
control elements (e.g., promoter, enhancer, sequences,
transcription terminators, polyadenylation sites, etc.), and
a selectable marker. Following the introduction of the
foreign DNA, engineered cells may be allowed to grow for 1-2
30 days in an enriched media, and then are switched to a
selective media. The selectable marker in the recombinant
plasmid confers resistance to the selection and allows cells
to stably integrate the plasmid into their chromosomes and
grow to form foci that in turn can be cloned and expanded
35 into cell lines. This method may advantageously be used to
engineer cell lines that express the *fsh05* gene product.
Such engineered cell lines may be particularly useful in

screening and evaluation of compounds that affect the endogenous activity of the *fsh05* gene product.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, *et al.*, 1977, *Cell* 11, 223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska and Szybalski, 1962, *Proc. Natl. Acad. Sci. USA* 48, 2026), and adenine phosphoribosyltransferase (Lowy, *et al.*, 1980, *Cell* 22, 817) genes can be employed in *tk*⁻, *hgpRT*⁻ or *aprt* cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: *dhfr*, which confers resistance to methotrexate (Wigler, *et al.*, 1980, *Natl. Acad. Sci. USA* 77, 3567; O'Hare, *et al.*, 1981, *Proc. Natl. Acad. Sci. USA* 78, 1527); *gpt*, which confers resistance to mycophenolic acid (Mulligan and Berg, 1981, *Proc. Natl. Acad. Sci. USA* 78, 2072); *neo*, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, *et al.*, 1981, *J. Mol. Biol.* 150, 1); and *hygro*, which confers resistance to hygromycin (Santerre, *et al.*, 1984, *Gene* 30, 147).

Alternatively, any fusion protein may be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht, *et al.* allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht, *et al.*, 1991, *Proc. Natl. Acad. Sci. USA* 88, 8972-8976). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni²⁺-nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

The *fsh05* gene products can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, goats, sheep, and non-human primates, *e.g.*,

baboons, monkeys, and chimpanzees may be used to generate *fsh05* transgenic animals. The term "transgenic," as used herein, refers to animals expressing *fsh05* gene sequences from a different species (e.g., mice expressing human *fsh05* sequences), as well as animals that have been genetically engineered to overexpress endogenous (i.e., same species) *fsh05* sequences or animals that have been genetically engineered to no longer express endogenous *fsh05* gene sequences (i.e., "knock-out" animals), and their progeny.

10 Any technique known in the art may be used to introduce an *fsh05* gene transgene into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to pronuclear microinjection (Hoppe and Wagner, 1989, U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten, et al., 1985, Proc. Natl. Acad. Sci., USA 82, 6148-6152); gene targeting in embryonic stem cells (Thompson, et al., 1989, Cell 56, 313-321); electroporation of embryos (Lo, 1983, Mol. Cell. Biol. 3, 1803-1814); and sperm-mediated gene transfer (Lavitrano et al., 1989, Cell 57, 717-723) (For a review of such techniques, see Gordon, 1989, Transgenic Animals, Intl. Rev. Cytol. 115, 171-229)

Any technique known in the art may be used to produce transgenic animal clones containing an *fsh05* transgene, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal or adult cells induced to quiescence (Campbell, et al., 1996, Nature 380, 64-66; Wilmut, et al., Nature 385, 810-813).

The present invention provides for transgenic animals that carry an *fsh05* transgene in all their cells, as well as animals that carry the transgene in some, but not all their cells, i.e., mosaic animals. The transgene may be integrated as a single transgene or in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko, et al., 1992, Proc. Natl. Acad. Sci.

USA 89, 6232-6236). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the *fsh05* gene transgene be integrated into the chromosomal site of the endogenous *fsh05* gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous *fsh05* gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous *fsh05* gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous *fsh05* gene in only that cell type, by following, for example, the teaching of Gu, et al. (Gu, et al., 1994, Science 265, 103-106). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant *fsh05* gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques that include but are not limited to Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and RT-PCR (reverse transcriptase PCR). Samples of *fsh05* gene-expressing tissue, may also be evaluated immunocytochemically using antibodies specific for the *fsh05* transgene product.

5.3. ANTIBODIES TO *fsh05* GENE PRODUCTS

Described herein are methods for the production of antibodies capable of specifically recognizing one or more

fsh05 gene product epitopes or epitopes of conserved variants or peptide fragments of the *fsh05* gene products.

Such antibodies may include, but are not limited to, polyclonal antibodies, monoclonal antibodies (mAbs),
5 humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Such antibodies may be used, for example, in the detection of a
10 *fsh05* gene product in an biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby patients may be tested for abnormal levels of *fsh05* gene products, and/or for the presence of abnormal forms of such gene products. Such antibodies may also be
15 utilized in conjunction with, for example, compound screening schemes, as described, below, in Section 5.8, for the evaluation of the effect of test compounds on *fsh05* gene product levels and/or activity. Additionally, such antibodies can be used in conjunction with the gene therapy
20 techniques described, below, in Section 5.9.0.2 to, for example, evaluate the normal and/or engineered *fsh05*-expressing cells prior to their introduction into the patient.

Anti-*fsh05* gene product antibodies may additionally
25 be used as a method for the inhibition of abnormal *fsh05* gene product activity. Thus, such antibodies may, therefore, be utilized as part of treatment methods for an *fsh05* disorder or a neuropsychiatric disorder, such as BAD.

For the production of antibodies against a *fsh05*
30 gene product, various host animals may be immunized by injection with a *fsh05* gene product, or a portion thereof. Such host animals may include, but are not limited to rabbits, mice, and rats, to name but a few. Various adjuvants may be used to increase the immunological response,
35 depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as

lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*.

5 Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as a *fsh05* gene product, or an antigenic functional derivative thereof. For the production of polyclonal antibodies, host animals such as
10 those described above, may be immunized by injection with *fsh05* gene product supplemented with adjuvants as also described above.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be
15 obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, Nature 256, 495-497; and U.S. Patent No. 4,376,110), the human B-cell hybridoma
20 technique (Kosbor et al., 1983, Immunology Today 4, 72; Cole et al., 1983, Proc. Natl. Acad. Sci. USA 80, 2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class
25 including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated *in vitro* or *in vivo*. Production of high titers of mAbs *in vivo* makes this the presently preferred method of production.

30 In addition, techniques developed for the production of "chimeric antibodies" (Morrison, et al., 1984, Proc. Natl. Acad. Sci., 81, 6851-6855; Neuberger, et al., 1984, Nature 312, 604-608; Takeda, et al., 1985, Nature, 314, 452-454) by splicing the genes from a mouse antibody molecule
35 of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which

different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. (See, e.g., Cabilly et al., U.S. Patent No. 4,816,567; and Boss et al.,
5 U.S. Patent No. 4,816397, which are incorporated herein by reference in their entirety.)

In addition, techniques have been developed for the production of humanized antibodies. (See, e.g., Queen, U.S. Patent No. 5,585,089, which is incorporated herein by
10 reference in its entirety.) An immunoglobulin light or heavy chain variable region consists of a "framework" region interrupted by three hypervariable regions, referred to as complementarity determining regions (CDRs). The extent of the framework region and CDRs have been precisely defined
15 (see, "Sequences of Proteins of Immunological Interest", Kabat, E. et al., U.S. Department of Health and Human Services (1983). Briefly, humanized antibodies are antibody molecules from non-human species having one or more CDRs from the non-human species and a framework region from a human
20 immunoglobulin molecule.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778; Bird, 1988, Science 242, 423-426; Huston, et al., 1988, Proc. Natl. Acad. Sci. USA 85, 5879-5883; and Ward, et al., 1989,
25 Nature 334, 544-546) can be adapted to produce single chain antibodies against *fsh05* gene products. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

30 Antibody fragments that recognize specific epitopes may be generated by known techniques. For example, such fragments include but are not limited to: the $F(ab')_2$ fragments, which can be produced by pepsin digestion of the antibody molecule and the Fab fragments, which can be
35 generated by reducing the disulfide bridges of the $F(ab')_2$ fragments. Alternatively, Fab expression libraries may be constructed (Huse, et al., 1989, Science, 246, 1275-1281) to

allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

5.4. USES OF *fsh05* GENE SEQUENCES,
GENE PRODUCTS, AND ANTIBODIES

5

Described herein are various applications of *fsh05* gene sequences, *fsh05* gene products, including peptide fragments and fusion proteins thereof, and of antibodies directed against *fsh05* gene products and peptide fragments
10 thereof. Such applications include, for example, prognostic and diagnostic evaluation of a *fsh05* disorder or a neuropsychiatric disorder, such as BAD, and the identification of subjects with a predisposition to such disorders, as described, below, in Section 5.5.
15 Additionally, such applications include methods for the treatment of a *fsh05* disorder or a neuropsychiatric disorder, such as BAD, as described, below, in Section 5.9, and for the identification of compounds that modulate the expression of the *fsh05* gene and/or the synthesis or activity of the *fsh05*
20 gene product, as described below, in Section 5.8. Such compounds can include, for example, other cellular products that are involved in mood regulation and in *fsh05* disorders and neuropsychiatric disorders, such as BAD. These compounds can be used, for example, in the amelioration of *fsh05*
25 disorders and neuropsychiatric disorders, such as BAD.

5.5. DIAGNOSIS OF ABNORMALITIES OF A *fsh05*
OR A NEUROPSYCHIATRIC DISORDER

A variety of methods can be employed for the
30 diagnostic and prognostic evaluation of *fsh05* disorders and neuropsychiatric disorders, such as BAD, and for the identification of subjects having a predisposition to such disorders.

Such methods may, for example, utilize reagents
35 such as the *fsh05* gene nucleotide sequences described in Sections 5.1, and antibodies directed against *fsh05* gene products, including peptide fragments thereof, as described,

above, in Section 5.3. Specifically, such reagents may be used, for example, for:

- (1) the detection of the presence of *fsh05* gene mutations, or the detection of either over- or under-
5 expression of *fsh05* gene mRNA relative to the state of a *fsh05* disorder or a neuropsychiatric disorder, such as BAD;
- (2) the detection of either an over- or an under-
abundance of *fsh05* gene product relative to the unaffected state; and
- 10 (3) the detection of an aberrant level of *fsh05* gene product activity relative to the unaffected state.

fsh05 gene nucleotide sequences can, for example, be used to diagnose an *fsh05* or neuropsychiatric disorder using, for example, the techniques for *fsh05* mutation
15 detection described above in Section 5.1.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one specific *fsh05* gene nucleic acid or anti-*fsh05* gene antibody reagent described herein, which may be
20 conveniently used, e.g., in clinical settings, to diagnose patients exhibiting abnormalities of a *fsh05* disorder or a neuropsychiatric disorder, such as BAD.

For the detection of *fsh05* mutations, any nucleated cell can be used as a starting source for genomic nucleic
25 acid. For the detection of *fsh05* gene expression or *fsh05* gene products, any cell type or tissue in which the *fsh05* gene is expressed may be utilized.

Nucleic acid-based detection techniques are described, below, in Section 5.6. Peptide detection
30 techniques are described, below, in Section 5.7.

5.6. DETECTION OF *fsh05* NUCLEIC ACID MOLECULES

A variety of methods can be employed to screen for
35 the presence of *fsh05* mutations and to detect and/or assay levels of *fsh05* nucleic acid sequences.

Mutations within the *fsh05* gene can be detected by utilizing a number of techniques. Nucleic acid from any nucleated cell can be used as the starting point for such assay techniques, and may be isolated according to standard
5 nucleic acid preparation procedures that are well known to those of skill in the art.

fsh05 nucleic acid sequences may be used in hybridization or amplification assays of biological samples to detect abnormalities involving *fsh05* gene structure,
10 including point mutations, insertions, deletions, inversions, translocations and chromosomal rearrangements. Such assays may include, but are not limited to, Southern analyses, single-stranded conformational polymorphism analyses (SSCP), and PCR analyses.

15 Diagnostic methods for the detection of *fsh05* gene-specific mutations can involve for example, contacting and incubating nucleic acids including recombinant DNA molecules, cloned genes or degenerate variants thereof, obtained from a sample, e.g., derived from a patient sample or other
20 appropriate cellular source, with one or more labeled nucleic acid reagents including recombinant DNA molecules, cloned genes or degenerate variants thereof, as described in Section 5.1, under conditions favorable for the specific annealing of these reagents to their complementary sequences within the
25 *fsh05* gene. Preferably, the lengths of these nucleic acid reagents are at least 15 to 30 nucleotides. After incubation, all non-annealed nucleic acids are removed from the nucleic acid:*fsh05* molecule hybrid. The presence of nucleic acids that have hybridized, if any such molecules
30 exist, is then detected. Using such a detection scheme, the nucleic acid from the cell type or tissue of interest can be immobilized, for example, to a solid support such as a membrane, or a plastic surface such as that on a microtiter plate or polystyrene beads. In this case, after incubation,
35 non-annealed, labeled nucleic acid reagents of the type described in Section 5.1 are easily removed. Detection of the remaining, annealed, labeled *fsh05* nucleic acid reagents

is accomplished using standard techniques well-known to those in the art. The *fsh05* gene sequences to which the nucleic acid reagents have annealed can be compared to the annealing pattern expected from a normal *fsh05* gene sequence in order
5 to determine whether a *fsh05* gene mutation is present.

Alternative diagnostic methods for the detection of *fsh05* gene specific nucleic acid molecules, in patient samples or other appropriate cell sources, may involve their amplification, e.g., by PCR (the experimental embodiment set
10 forth in Mullis, 1987, U.S. Patent No. 4,683,202), followed by the detection of the amplified molecules using techniques well known to those of skill in the art. The resulting amplified sequences can be compared to those that would be expected if the nucleic acid being amplified contained only
15 normal copies of the *fsh05* gene in order to determine whether a *fsh05* gene mutation exists.

Additionally, well-known genotyping techniques can be performed to identify individuals carrying *fsh05* gene mutations. Such techniques include, for example, the use of
20 restriction fragment length polymorphisms (RFLPs), which involve sequence variations in one of the recognition sites for the specific restriction enzyme used.

Additionally, improved methods for analyzing DNA polymorphisms, which can be utilized for the identification
25 of *fsh05* gene mutations, have been described that capitalize on the presence of variable numbers of short, tandemly repeated DNA sequences between the restriction enzyme sites. For example, Weber (U.S. Pat. No. 5,075,217) describes a DNA marker based on length polymorphisms in blocks of (dC-dA)n-
30 (dG-dT)n short tandem repeats. The average separation of (dC-dA)n-(dG-dT)n blocks is estimated to be 30,000-60,000 bp. Markers that are so closely spaced exhibit a high frequency co-inheritance, and are extremely useful in the identification of genetic mutations, such as, for example,
35 mutations within the *fsh05* gene, and the diagnosis of diseases and disorders related to *fsh05* mutations.

Also, Caskey et al. (U.S. Pat.No. 5,364,759) describe a DNA profiling assay for detecting short tri and tetra nucleotide repeat sequences. The process includes extracting the DNA of interest, such as the *fsh05* gene, 5 amplifying the extracted DNA, and labelling the repeat sequences to form a genotypic map of the individual's DNA.

The level of *fsh05* gene expression can also be assayed. For example, RNA from a cell type or tissue known, or suspected, to express the *fsh05* gene, such as brain, may 10 be isolated and tested utilizing hybridization or PCR techniques such as are described, above. The isolated cells can be derived from cell culture or from a patient. The analysis of cells taken from culture may be a necessary step in the assessment of cells to be used as part of a cell-based 15 gene therapy technique or, alternatively, to test the effect of compounds on the expression of the *fsh05* gene. Such analyses may reveal both quantitative and qualitative aspects of the expression pattern of the *fsh05* gene, including activation or inactivation of *fsh05* gene expression.

20 In one embodiment of such a detection scheme, a cDNA molecule is synthesized from an RNA molecule of interest (e.g., by reverse transcription of the RNA molecule into cDNA). A sequence within the cDNA is then used as the template for a nucleic acid amplification reaction, such as a 25 PCR amplification reaction, or the like. The nucleic acid reagents used as synthesis initiation reagents (e.g., primers) in the reverse transcription and nucleic acid amplification steps of this method are chosen from among the *fsh05* gene nucleic acid reagents described in Section 5.1. 30 The preferred lengths of such nucleic acid reagents are at least 9-30 nucleotides. For detection of the amplified product, the nucleic acid amplification may be performed using radioactively or non-radioactively labeled nucleotides. Alternatively, enough amplified product may be made such that 35 the product may be visualized by standard ethidium bromide staining or by utilizing any other suitable nucleic acid staining method.

Additionally, it is possible to perform such *fsh05* gene expression assays "in situ", i.e., directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary. Nucleic acid reagents such as those described in Section 5.1 may be used as probes and/or primers for such in situ procedures (see, for example, Nuovo, G.J., 1992, "PCR In Situ Hybridization: Protocols And Applications", Raven Press, NY).

Alternatively, if a sufficient quantity of the appropriate cells can be obtained, standard Northern analysis can be performed to determine the level of mRNA expression of the *fsh05* gene.

5.7. DETECTION OF *fsh05* GENE PRODUCTS

Antibodies directed against unimpaired or mutant *fsh05* gene products or conserved variants or peptide fragments thereof, which are discussed, above, in Section 5.3, may also be used as diagnostics and prognostics for a *fsh05* disorder or a neuropsychiatric disorder, such as BAD, as described herein. Such methods may be used to detect abnormalities in the level of *fsh05* gene product synthesis or expression, or abnormalities in the structure, temporal expression, and/or physical location of *fsh05* gene product. The antibodies and immunoassay methods described below have, for example, important *in vitro* applications in assessing the efficacy of treatments for *fsh05* disorders or neuropsychiatric disorders, such as BAD. Antibodies, or fragments of antibodies, such as those described below, may be used to screen potentially therapeutic compounds *in vitro* to determine their effects on *fsh05* gene expression and *fsh05* peptide production. The compounds that have beneficial effects on an *fsh05* disorder or a neuropsychiatric disorder, such as BAD, can be identified, and a therapeutically effective dose determined.

In vitro immunoassays may also be used, for example, to assess the efficacy of cell-based gene therapy

for an *fsh05* disorder or a neuropsychiatric disorder, such as BAD. Antibodies directed against *fsh05* peptides may be used *in vitro* to determine, for example, the level of *fsh05* gene expression achieved in cells genetically engineered to
5 produce *fsh05* peptides. In the case of intracellular *fsh05* gene products, such an assessment is done, preferably, using cell lysates or extracts. Such analysis will allow for a determination of the number of transformed cells necessary to achieve therapeutic efficacy *in vivo*, as well as optimization
10 of the gene replacement protocol.

The tissue or cell type to be analyzed will generally include those that are known, or suspected, to express the *fsh05* gene. The protein isolation methods employed herein may, for example, be such as those described
15 in Harlow and Lane (1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New Ycrk). The isolated cells can be derived from cell culture or from a patient. The analysis of cells taken from culture may be a necessary step in the assessment of cells to be used
20 as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of the *fsh05* gene.

Preferred diagnostic methods for the detection of *fsh05* gene products or conserved variants or peptide
25 fragments thereof, may involve, for example, immunoassays wherein the *fsh05* gene products or conserved variants or peptide fragments are detected by their interaction with an anti-*fsh05* gene product-specific antibody.

For example, antibodies, or fragments of
30 antibodies, such as those described, above, in Section 5.3, useful in the present invention, may be used to quantitatively or qualitatively detect the presence of *fsh05* gene products or conserved variants or peptide fragments thereof. This can be accomplished, for example, by immunofluorescence
35 techniques employing a fluorescently labeled antibody (see below, this Section) coupled with light microscopic, flow cytometric, or fluorimetric detection. Such techniques are

especially preferred for *fsh05* gene products that are expressed on the cell surface.

The antibodies (or fragments thereof) useful in the present invention may, additionally, be employed
5 histologically, as in immunofluorescence or immunoelectron microscopy, for *in situ* detection of *fsh05* gene products or conserved variants or peptide fragments thereof. *In situ* detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labeled
10 antibody of the present invention. The antibody (or fragment) is preferably applied by overlaying the labeled antibody (or fragment) onto a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of the *fsh05* gene product, or conserved variants
15 or peptide fragments, but also its distribution in the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve such *in situ* detection.

20 Immunoassays for *fsh05* gene products or conserved variants or peptide fragments thereof will typically comprise incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of cells, that have been incubated in cell culture, in the presence of a
25 detectably labeled antibody capable of identifying *fsh05* gene products or conserved variants or peptide fragments thereof, and detecting the bound antibody by any of a number of techniques well-known in the art.

The biological sample may be brought in contact
30 with and immobilized onto a solid phase support or carrier such as nitrocellulose, or other solid support that is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the detectably labeled
35 *fsh05* gene specific antibody. The solid phase support may then be washed with the buffer a second time to remove

unbound antibody. The amount of bound label on solid support may then be detected by conventional means.

By "solid phase support or carrier" is intended any support capable of binding an antigen or an antibody. Well-
5 known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the
10 present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test
15 tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by
20 use of routine experimentation.

The binding activity of a given lot of anti-*fsh05* gene product antibody may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each
25 determination by employing routine experimentation.

One of the ways in which the *fsh05* gene peptide-specific antibody can be detectably labeled is by linking the same to an enzyme and use in an enzyme immunoassay (EIA) (Voller, A., "The Enzyme Linked Immunosorbent Assay (ELISA)",
30 1978, Diagnostic Horizons 2, 1-7, Microbiological Associates Quarterly Publication, Walkersville, MD); Voller, A. et al., 1978, J. Clin. Pathol. 31, 507-520; Butler, J.E., 1981, Meth. Enzymol. 73, 482-523; Maggio, E. (ed.), 1980, Enzyme Immunoassay, CRC Press, Boca Raton, FL; Ishikawa, E. et al.,
35 (eds.), 1981, Enzyme Immunoassay, Kigaku Shoin, Tokyo). The enzyme which is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in

such a manner as to produce a chemical moiety that can be detected, for example, by spectrophotometric, fluorimetric or by visual means. Enzymes that can be used to detectably label the antibody include, but are not limited to, malate
5 dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, α -glycerophosphate, dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, β -galactosidase, ribonuclease, urease, catalase,
10 glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. The detection can be accomplished by colorimetric methods that employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate
15 in comparison with similarly prepared standards.

Detection may also be accomplished using any of a variety of other immunoassays. For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect *fsh05* gene peptides through the use of a
20 radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986). The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or
25 by autoradiography.

It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the
30 most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, *o*-phthaldehyde and fluorescamine.

The antibody can also be detectably labeled using
35 fluorescence emitting metals such as ^{152}Eu , or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as

diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of
5 the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, therromatic acridinium ester, imidazole,
10 acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the
15 chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

20 5.8. SCREENING ASSAYS FOR COMPOUNDS
THAT MODULATE *fsh05* GENE ACTIVITY

The following assays are designed to identify compounds that bind to a *fsh05* gene product, intracellular proteins or portions of proteins that interact with a *fsh05*
25 gene product, compounds that interfere with the interaction of a *fsh05* gene product with intracellular proteins and compounds that modulate the activity of *fsh05* gene (*i.e.*, modulate the level of *fsh05* gene expression and/or modulate the level of *fsh05* gene product activity). Assays may
30 additionally be utilized that identify compounds that bind to *fsh05* gene regulatory sequences (*e.g.*, promoter sequences; see *e.g.*, Platt, 1994, J. Biol. Chem. 269, 28558-28562), and that may modulate the level of *fsh05* gene expression. Compounds may include, but are not limited to, small organic
35 molecules, such as ones that are able to cross the blood-brain barrier, gain entry into an appropriate cell and affect

expression of the *fsh05* gene or some other gene involved in a *fsh05* regulatory pathway, or intracellular proteins.

Methods for the identification of such intracellular proteins are described, below, in Section 5.8.2. Such intracellular proteins may be involved in the control and/or regulation of mood. Further, among these compounds are compounds that affect the level of *fsh05* gene expression and/or *fsh05* gene product activity and that can be used in the therapeutic treatment of *fsh05* disorders or neuropsychiatric disorders such as BAD, as described, below, in Section 5.9.

Compounds may include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to, Ig-tailed fusion peptides, and members of random peptide libraries; (see, e.g., Lam, et al., 1991, Nature 354, 82-84; Houghten, et al., 1991, Nature 354, 84-86), and combinatorial chemistry-derived molecular library made of D- and/or L- configuration amino acids, phosphopeptides (including, but not limited to members of random or partially degenerate, directed phosphopeptide libraries; see, e.g., Songyang, et al., 1993, Cell 72, 767-778), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb, F(ab')₂ and FAb expression library fragments, and epitope-binding fragments thereof), and small organic or inorganic molecules.

Such compounds may further comprise compounds, in particular drugs or members of classes or families of drugs, known to ameliorate or exacerbate the symptoms of a neuropsychiatric disorder such as BAD. Such compounds include antidepressants such as lithium salts, carbamazepine, valproic acid, lysergic acid diethylamide (LSD), *p*-chlorophenylalanine, *p*-propyldopacetamide dithiocarbamate derivatives e.g., FLA 63; anti-anxiety drugs, e.g., diazepam; monoamine oxidase (MAO) inhibitors, e.g., iproniazid, clorgyline, phenelzine and isocarboxazid; biogenic amine uptake blockers, e.g., tricyclic

antidepressants such as desipramine, imipramine and amitriptyline; serotonin reuptake inhibitors e.g., fluoxetine; antipsychotic drugs such as phenothiazine derivatives (e.g., chlorpromazine (thorazine) and 5 trifluopromazine)), butyrophenones (e.g., haloperidol (Haldol)), thioxanthene derivatives (e.g., chlorprothixene), and dibenzodiazepines (e.g., clozapine); benzodiazepines; dopaminergic agonists and antagonists e.g., L-DOPA, cocaine, amphetamine, α -methyl-tyrosine, reserpine, tetrabenazine, 10 benzotropine, pargyline; noradrenergic agonists and antagonists e.g., clonidine, phenoxybenzamine, phentolamine, tropolone.

Compounds identified via assays such as those described herein may be useful, for example, in elaborating 15 the biological function of the *fsh05* gene product, and for ameliorating *fsh05* disorders or neuropsychiatric disorders, such as BAD. Assays for testing the effectiveness of compounds, identified by, for example, techniques such as those described in Sections 5.8.1 - 5.8.3, are discussed, 20 below, in Section 5.8.4.

5.8.1. IN VITRO SCREENING ASSAYS FOR COMPOUNDS THAT BIND TO THE *fsh05* GENE PRODUCT

In vitro systems may be designed to identify 25 compounds capable of binding the *fsh05* gene products of the invention. Compounds identified may be useful, for example, in modulating the activity of unimpaired and/or mutant *fsh05* gene products, may be useful in elaborating the biological function of the *fsh05* gene product, may be utilized in 30 screens for identifying compounds that disrupt normal *fsh05* gene product interactions, or may in themselves disrupt such interactions.

The principle of the assays used to identify compounds that bind to the *fsh05* gene product involves 35 preparing a reaction mixture of the *fsh05* gene product and the test compound under conditions and for a time sufficient to allow the two components to interact and bind, thus

forming a complex that can be removed and/or detected in the reaction mixture. These assays can be conducted in a variety of ways. For example, one method to conduct such an assay would involve anchoring *fsh05* gene product or the test
5 substance onto a solid phase and detecting *fsh05* gene product/test compound complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, the *fsh05* gene product may be anchored onto a solid surface, and the test compound, which is not anchored, may be
10 labeled, either directly or indirectly.

In practice, microtiter plates may conveniently be utilized as the solid phase. The anchored component may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished by simply coating the
15 solid surface with a solution of the protein and drying. Alternatively, an immobilized antibody, preferably a monoclonal antibody, specific for the protein to be immobilized may be used to anchor the protein to the solid surface. The surfaces may be prepared in advance and stored.

20 In order to conduct the assay, the non-immobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that any complexes formed will remain
25 immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously non-immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the
30 previously non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the previously non-immobilized component (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled
35 anti-Ig antibody).

Alternatively, a reaction can be conducted in a liquid phase, the reaction products separated from unreacted

components, and complexes detected; e.g., using an immobilized antibody specific for *fsh05* gene product or the test compound to anchor any complexes formed in solution, and a labeled antibody specific for the other component of the possible complex to detect anchored complexes.

5.8.2. ASSAYS FOR INTRACELLULAR PROTEINS THAT INTERACT WITH *fsh05* GENE PRODUCTS

Any method suitable for detecting protein-protein interactions may be employed for identifying *fsh05* protein-protein interactions.

Among the traditional methods that may be employed are co-immunoprecipitation, cross-linking and co-purification through gradients or chromatographic columns. Utilizing procedures such as these allows for the identification of proteins, including intracellular proteins, that interact with *fsh05* gene products. Once isolated, such a protein can be identified and can be used in conjunction with standard techniques, to identify proteins it interacts with. For example, at least a portion of the amino acid sequence of a protein that interacts with the *fsh05* gene product can be ascertained using techniques well known to those of skill in the art, such as via the Edman degradation technique (see, e.g., Creighton, 1983, "Proteins: Structures and Molecular Principles," W.H. Freeman & Co., N.Y., pp.34-49). The amino acid sequence obtained may be used as a guide for the generation of oligonucleotide mixtures that can be used to screen for gene sequences encoding such proteins. Screening made be accomplished, for example, by standard hybridization or PCR techniques. Techniques for the generation of oligonucleotide mixtures and the screening are well-known. (See, e.g., Ausubel, *supra*, and 1990, "PCR Protocols: A Guide to Methods and Applications," Innis, et al., eds. Academic Press, Inc., New York).

Additionally, methods may be employed that result in the simultaneous identification of genes that encode the a protein which interacts with an *fsh05* protein. These methods

include, for example, probing expression libraries with labeled *fsh05* protein, using *fsh05* protein in a manner similar to the well known technique of antibody probing of λ gt11 libraries.

5 One method that detects protein interactions *in vivo*, the two-hybrid system, is described in detail for illustration only and not by way of limitation. One version of this system has been described (Chien, et al., 1991, Proc. Natl. Acad. Sci. USA, 88, 9578-9582) and is commercially
10 available from Clontech (Palo Alto, CA).

Briefly, utilizing such a system, plasmids are constructed that encode two hybrid proteins: one consists of the DNA-binding domain of a transcription activator protein fused to the *fsh05* gene product and the other consists of the
15 transcription activator protein's activation domain fused to an unknown protein that is encoded by a cDNA that has been recombined into this plasmid as part of a cDNA library. The DNA-binding domain fusion plasmid and the cDNA library are transformed into a strain of the yeast *Saccharomyces*
20 *cerevisiae* that contains a reporter gene (e.g., HBS or *lacZ*) whose regulatory region contains the transcription activator's binding site. Either hybrid protein alone cannot activate transcription of the reporter gene: the DNA-binding domain hybrid cannot because it does not provide activation
25 function and the activation domain hybrid cannot because it cannot localize to the activator's binding sites. Interaction of the two hybrid proteins reconstitutes the functional activator protein and results in expression of the reporter gene, which is detected by an assay for the reporter
30 gene product.

The two-hybrid system or related methodology may be used to screen activation domain libraries for proteins that interact with the "bait" gene product. By way of example, and not by way of limitation, *fsh05* gene products may be used
35 as the bait gene product. Total genomic or cDNA sequences are fused to the DNA encoding an activation domain. This library and a plasmid encoding a hybrid of a bait *fsh05* gene

product fused to the DNA-binding domain are co-transformed into a yeast reporter strain, and the resulting transformants are screened for those that express the reporter gene. For example, and not by way of limitation, a bait *fsh05* gene
5 sequence, such as the open reading frame of the *fsh05* gene, can be cloned into a vector such that it is translationally fused to the DNA encoding the DNA-binding domain of the GAL4 protein. These colonies are purified and the library plasmids responsible for reporter gene expression are
10 isolated. DNA sequencing is then used to identify the proteins encoded by the library plasmids.

A cDNA library of the cell line from which proteins that interact with bait *fsh05* gene product are to be detected can be made using methods routinely practiced in the art.
15 According to the particular system described herein, for example, the cDNA fragments can be inserted into a vector such that they are translationally fused to the transcriptional activation domain of GAL4. This library can be co-transformed along with the bait *fsh05* gene-GAL4 fusion
20 plasmid into a yeast strain that contains a lacZ gene driven by a promoter that contains GAL4 activation sequence. A cDNA encoded protein, fused to GAL4 transcriptional activation domain, that interacts with bait *fsh05* gene product will reconstitute an active GAL4 protein and thereby drive
25 expression of the HIS3 gene. Colonies that express HIS3 can be detected by their growth on petri dishes containing semi-solid agar based media lacking histidine. The cDNA can then be purified from these strains, and used to produce and isolate the bait *fsh05* gene-interacting protein using
30 techniques routinely practiced in the art.

5.8.3. ASSAYS FOR COMPOUNDS THAT INTERFERE WITH *fsh05* GENE PRODUCT MACROMOLECULE INTERACTION

fsh05 gene products of the invention may, *in vivo*,
35 interact with one or more macromolecules, including intracellular macromolecules, such as proteins. Such macromolecules may include, but are not limited to, nucleic

acid molecules and those proteins identified via methods such as those described, above, in Sections 5.8.1 - 5.8.2. For purposes of this discussion, the macromolecules are referred to herein as "binding partners". Compounds that disrupt
5 *fsh05* binding in this way may be useful in regulating the activity of the *fsh05* gene product, especially mutant *fsh05* gene products. Such compounds may include, but are not limited to molecules such as peptides, and the like, as described, for example, in Section 5.8.2 above, which would
10 be capable of gaining access to an *fsh05* gene product.

The basic principle of the assay systems used to identify compounds that interfere with the interaction between the *fsh05* gene product and its binding partner or partners involves preparing a reaction mixture containing the
15 *fsh05* gene product, and the binding partner under conditions and for a time sufficient to allow the two to interact and bind, thus forming a complex. In order to test a compound for inhibitory activity, the reaction mixture is prepared in the presence and absence of the test compound. The test
20 compound may be initially included in the reaction mixture, or may be added at a time subsequent to the addition of *fsh05* gene product and its binding partner. Control reaction mixtures are incubated without the test compound or with a placebo. The formation of any complexes between the *fsh05*
25 gene protein and the binding partner is then detected. The formation of a complex in the control reaction, but not in the reaction mixture containing the test compound, indicates that the compound interferes with the interaction of the *fsh05* gene protein and the interactive binding partner.
30 Additionally, complex formation within reaction mixtures containing the test compound and normal *fsh05* gene protein may also be compared to complex formation within reaction mixtures containing the test compound and a mutant *fsh05* gene protein. This comparison may be important in those cases
35 wherein it is desirable to identify compounds that disrupt interactions of mutant but not normal *fsh05* gene proteins.

The assay for compounds that interfere with the interaction of the *fsh05* gene products and binding partners can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the *fsh05* gene product or the binding partner onto a solid phase and detecting complexes anchored on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere with the interaction between the *fsh05* gene products and the binding partners, e.g., by competition, can be identified by conducting the reaction in the presence of the test substance; i.e., by adding the test substance to the reaction mixture prior to or simultaneously with the *fsh05* gene protein and interactive intracellular binding partner. Alternatively, test compounds that disrupt preformed complexes, e.g., compounds with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed. The various formats are described briefly below.

In a heterogeneous assay system, either the *fsh05* gene product or the interactive binding partner, is anchored onto a solid surface, while the non-anchored species is labeled, either directly or indirectly. In practice, microtiter plates are conveniently utilized. The anchored species may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished simply by coating the solid surface with a solution of the *fsh05* gene product or binding partner and drying. Alternatively, an immobilized antibody specific for the species to be anchored may be used to anchor the species to the solid surface. The surfaces may be prepared in advance and stored.

In order to conduct the assay, the partner of the immobilized species is exposed to the coated surface with or

without the test compound. After the reaction is complete, unreacted components are removed (e.g., by washing) and any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the non-immobilized species is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the non-immobilized species is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the initially non-immobilized species (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds that inhibit complex formation or that disrupt preformed complexes can be detected.

Alternatively, the reaction can be conducted in a liquid phase in the presence or absence of the test compound, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes. Again, depending upon the order of addition of reactants to the liquid phase, test compounds that inhibit complex or that disrupt preformed complexes can be identified.

In an alternate embodiment of the invention, a homogeneous assay can be used. In this approach, a preformed complex of the *fsh05* gene protein and the interactive binding partner is prepared in which either the *fsh05* gene product or its binding partners is labeled, but the signal generated by the label is quenched due to complex formation (see, e.g., U.S. Patent No. 4,109,496 by Rubenstein which utilizes this approach for immunoassays). The addition of a test substance that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way, test substances that disrupt

fsh05 gene protein/binding partner interaction can be identified.

In a particular embodiment, the *fsh05* gene product can be prepared for immobilization using recombinant DNA techniques described in Section 5.2. above. For example, the *fsh05* coding region can be fused to a glutathione-S-transferase (GST) gene using a fusion vector, such as pGEX-5X-1, in such a manner that its binding activity is maintained in the resulting fusion protein. The interactive binding partner can be purified and used to raise a monoclonal antibody, using methods routinely practiced in the art and described above, in Section 5.3. This antibody can be labeled with the radioactive isotope ¹²⁵I, for example, by methods routinely practiced in the art. In a heterogeneous assay, e.g., the GST-*fsh05* fusion protein can be anchored to glutathione-agarose beads. The interactive binding partner can then be added in the presence or absence of the test compound in a manner that allows interaction and binding to occur. At the end of the reaction period, unbound material can be washed away, and the labeled monoclonal antibody can be added to the system and allowed to bind to the complexed components. The interaction between the *fsh05* gene protein and the interactive binding partner can be detected by measuring the amount of radioactivity that remains associated with the glutathione-agarose beads. A successful inhibition of the interaction by the test compound will result in a decrease in measured radioactivity.

Alternatively, the GST-*fsh05* gene fusion protein and the interactive binding partner can be mixed together in liquid in the absence of the solid glutathione-agarose beads. The test compound can be added either during or after the species are allowed to interact. This mixture can then be added to the glutathione-agarose beads and unbound material is washed away. Again the extent of inhibition of the *fsh05* gene product/binding partner interaction can be detected by adding the labeled antibody and measuring the radioactivity associated with the beads.

In another embodiment of the invention, these same techniques can be employed using peptide fragments that correspond to the binding domains of the *fsh05* protein and/or the interactive or binding partner (in cases where the binding partner is a protein), in place of one or both of the full length proteins. Any number of methods routinely practiced in the art can be used to identify and isolate the binding sites. These methods include, but are not limited to, mutagenesis of the gene encoding one of the proteins and screening for disruption of binding in a co-immunoprecipitation assay. Compensating mutations in the gene encoding the second species in the complex can then be selected. Sequence analysis of the genes encoding the respective proteins will reveal the mutations that correspond to the region of the protein involved in interactive binding. Alternatively, one protein can be anchored to a solid surface using methods described in this Section above, and allowed to interact with and bind to its labeled binding partner, which has been treated with a proteolytic enzyme, such as trypsin. After washing, a short, labeled peptide comprising the binding domain may remain associated with the solid material, which can be isolated and identified by amino acid sequencing. Also, once the gene coding for the segments can be engineered to express peptide fragments of the protein, which can then be tested for binding activity and purified or synthesized.

For example, and not by way of limitation, a *fsh05* gene product can be anchored to a solid material as described, above, in this Section by making a GST-*fsh05* fusion protein and allowing it to bind to glutathione agarose beads. The interactive binding partner obtained can be labeled with a radioactive isotope, such as ³⁵S, and cleaved with a proteolytic enzyme such as trypsin. Cleavage products can then be added to the anchored GST-*fsh05* fusion protein and allowed to bind. After washing away unbound peptides, labeled bound material, representing the binding partner binding domain, can be eluted, purified, and analyzed for

amino acid sequence by well-known methods. Peptides so identified can be produced synthetically or fused to appropriate facilitative proteins using recombinant DNA technology.

5

5.8.4. ASSAYS FOR IDENTIFICATION
OF COMPOUNDS THAT AMELIORATE A *fsh05*
DISORDER OR A NEUROPSYCHIATRIC DISORDER

Compounds, including but not limited to binding
10 compounds identified via assay techniques such as those
described, above, in Sections 5.8.1 - 5.8.4, can be tested
for the ability to ameliorate symptoms of a *fsh05* disorder or
a disorder of thought and/or mood, including thought
disorders such as schizophrenia, schizotypal personality
15 disorder; psychosis; mood disorders, such as schizoaffective
disorders (e.g., schizoaffective disorder manic type (SAD-M);
bipolar affective (mood) disorders, such as severe bipolar
affective (mood) disorder (BP-I), bipolar affective (mood)
disorder with hypomania and major depression (BP-II);
20 unipolar affective disorders, such as unipolar major
depressive disorder (MDD), dysthymic disorder; obsessive-
compulsive disorders; phobias, e.g., agoraphobia; panic
disorders; generalized anxiety disorders; somatization
disorders and hypochondriasis; and attention deficit
25 disorders. It should be noted that the assays described
herein can identify compounds that affect *fsh05* gene activity
by either affecting *fsh05* gene expression or by affecting the
level of *fsh05* gene product activity. For example, compounds
may be identified that are involved in another step in the
30 pathway in which the *fsh05* gene and/or *fsh05* gene product is
involved and, by affecting this same pathway may modulate the
effect of *fsh05* on the development of a neuropsychiatric
disorder such as BAD. Such compounds can be used as part of
a therapeutic method for the treatment of the disorder.

35 Described below are cell-based and animal model-
based assays for the identification of compounds exhibiting

such an ability to ameliorate symptoms of a *fsh05* disorder or a neuropsychiatric disorder, such as BAD.

First, cell-based systems can be used to identify compounds that may act to ameliorate symptoms of a *fsh05* disorder or a neuropsychiatric disorder, such as BAD. Such cell systems can include, for example, recombinant or non-recombinant cell, such as cell lines, that express the *fsh05* gene.

In utilizing such cell systems, cells that express *fsh05* may be exposed to a compound suspected of exhibiting an ability to ameliorate symptoms of a *fsh05* disorder or a neuropsychiatric disorder, such as BAD, at a sufficient concentration and for a sufficient time to elicit such an amelioration of such symptoms in the exposed cells. After exposure, the cells can be assayed to measure alterations in the expression of the *fsh05* gene, e.g., by assaying cell lysates for *fsh05* mRNA transcripts (e.g., by Northern analysis) or for *fsh05* gene products expressed by the cell; compounds that modulate expression of the *fsh05* gene are good candidates as therapeutics. Alternatively, the cells are examined to determine whether one or more cellular phenotypes associated with an *fsh05* disorder or a neuropsychiatric disorder, such as BAD, has been altered to resemble a more normal or unimpaired, unaffected phenotype, or a phenotype more likely to produce a lower incidence or severity of disorder symptoms.

In addition, animal-based systems or models for a *fsh05* disorder or a neuropsychiatric disorder, such as BAD, which may include, for example, *fsh05* mice, may be used to identify compounds capable of ameliorating symptoms of the disorder. Such animal models may be used as test substrates for the identification of drugs, pharmaceuticals, therapies and interventions that may be effective in treating such disorders. For example, animal models may be exposed to a compound suspected of exhibiting an ability to ameliorate symptoms, at a sufficient concentration and for a sufficient time to elicit such an amelioration of symptoms of a *fsh05*

disorder or a neuropsychiatric disorder, such as BAD, in the exposed animals. The response of the animals to the exposure may be monitored by assessing the reversal of such symptoms.

With regard to intervention, any treatments that
5 reverse any aspect of symptoms of a *fsh05* disorder or a neuropsychiatric disorder, such as BAD, should be considered as candidates for human therapeutic intervention in such a disorder. Dosages of test agents may be determined by deriving dose-response curves, as discussed in Section
10 5.10.1, below.

5.9. COMPOUNDS AND METHODS FOR THE TREATMENT OF *fsh05* DISORDERS OR NEUROPSYCHIATRIC DISORDERS

Described below are methods and compositions
15 whereby a *fsh05* disorder or a disorder of thought and/or mood, such as BAD, may be treated.

For example, such methods can comprise administering compounds which modulate the expression of a mammalian *fsh05* gene and/or the synthesis or activity of a
20 mammalian *fsh05* gene product so symptoms of the disorder are ameliorated.

Alternatively, in those instances whereby the mammalian *fsh05* or neuropsychiatric disorders result from *fsh05* gene mutations, such methods can comprise supplying the
25 mammal with a nucleic acid molecule encoding an unimpaired *fsh05* gene product such that an unimpaired *fsh05* gene product is expressed and symptoms of the disorder are ameliorated.

In another embodiment of methods for the treatment of mammalian *fsh05* or neuropsychiatric disorders resulting
30 from *fsh05* gene mutations, such methods can comprise supplying the mammal with a cell comprising a nucleic acid molecule that encodes an unimpaired *fsh05* gene product such that the cell expresses the unimpaired *fsh05* gene product and symptoms of the disorder are ameliorated.

35 In cases in which a loss of normal *fsh05* gene product function results in the development of a *fsh05* disorder or neuropsychiatric disorder phenotype, an increase in *fsh05*

gene product activity would facilitate progress towards an asymptomatic state in individuals exhibiting a deficient level of *fsh05* gene expression and/or *fsh05* gene product activity. Methods for enhancing the expression or synthesis 5 of *fsh05* can include, for example, methods such as those described below, in Section 5.9.2.

Alternatively, symptoms of *fsh05* disorders or neuropsychiatric disorders, such as BAD, may be ameliorated by administering a compound that decreases the level of *fsh05* 10 gene expression and/or *fsh05* gene product activity. Methods for inhibiting or reducing the level of *fsh05* synthesis or expression can include, for example, methods such as those described in Section 5.9.1.

In one embodiment of treatment methods, the 15 compounds administered do not comprise compounds, in particular drugs, reported to ameliorate or exacerbate the symptoms of a neuropsychiatric disorder, such as BAD. Such compounds include antidepressants such as lithium salts, carbamazepine, valproic acid, lysergic acid diethylamide 20 (LSD), *p*-chlorophenylalanine, *p*-propyldopacetamide dithiocarbamate derivatives e.g., FLA 63; anti-anxiety drugs, e.g., diazepam; monoamine oxidase (MAO) inhibitors, e.g., iproniazid, clorgyline, phenelzine and isocarboxazid; biogenic amine uptake blockers, e.g., tricyclic 25 antidepressants such as desipramine, imipramine and amitriptyline; serotonin reuptake inhibitors e.g., fluoxetine; antipsychotic drugs such as phenothiazine derivatives (e.g., chlorpromazine (thorazine) and trifluopromazine)), butyrophenones (e.g., haloperidol 30 (Haldol)), thioxanthene derivatives (e.g., chlorprothixene), and dibenzodiazepines (e.g., clozapine); benzodiazepines; dopaminergic agonists and antagonists e.g., L-DOPA, cocaine, amphetamine, α -methyl-tyrosine, reserpine, tetrabenazine, benzotropine, pargyline; noradrenergic agonists and 35 antagonists e.g., clonidine, phenoxybenzamine, phentolamine, tropolone.

5.9.1. INHIBITORY ANTISENSE, RIBOZYME
AND TRIPLE HELIX APPROACHES

In another embodiment, symptoms of certain *fsh05* disorders or neuropsychiatric disorders, such as BAD may be ameliorated by decreasing the level of *fsh05* gene expression and/or *fsh05* gene product activity by using *fsh05* gene sequences in conjunction with well-known antisense, gene "knock-out," ribozyme and/or triple helix methods to decrease the level of *fsh05* gene expression. Among the compounds that may exhibit the ability to modulate the activity, expression or synthesis of the *fsh05* gene, including the ability to ameliorate the symptoms of a *fsh05* disorder or a neuropsychiatric disorder, such as BAD, are antisense, ribozyme, and triple helix molecules. Such molecules may be designed to reduce or inhibit either unimpaired, or if appropriate, mutant target gene activity. Techniques for the production and use of such molecules are well known to those of skill in the art.

Antisense RNA and DNA molecules act to directly block the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. Antisense approaches involve the design of oligonucleotides that are complementary to a target gene mRNA. The antisense oligonucleotides will bind to the complementary target gene mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not required.

A sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can

ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

In one embodiment, oligonucleotides complementary
5 to non-coding regions of the *fsh05* gene could be used in an antisense approach to inhibit translation of endogenous *fsh05* mRNA. Antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In
10 specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

Regardless of the choice of target sequence, it is preferred that *in vitro* studies are first performed to
15 quantitate the ability of the antisense oligonucleotide to inhibit gene expression. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of oligonucleotides. It is also preferred that these studies
20 compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense oligonucleotide are compared with those obtained using a control oligonucleotide. It is preferred that the control
25 oligonucleotide is of approximately the same length as the test oligonucleotide and that the nucleotide sequence of the oligonucleotide differs from the antisense sequence no more than is necessary to prevent specific hybridization to the target sequence.

30 The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule,
35 hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport

across the cell membrane (see, e.g., Letsinger, et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86, 6553-6556; Lemaitre, et al., 1987, Proc. Natl. Acad. Sci. 84, 648-652; PCT Publication No. WO88/09810, published December 15, 1988) or
5 the blood-brain barrier (see, e.g., PCT Publication No. WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents (see, e.g., Krol et al., 1988, BioTechniques 6, 958-976) or intercalating agents (see, e.g., Zon, 1988, Pharm. Res. 5, 539-549). To this end, the
10 oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group
15 including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-
20 galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil,
25 beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-
30 5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group
35 including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an α -anomeric oligonucleotide. An α -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gautier, et al., 1987, Nucl. Acids Res. 15, 6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue, et al., 1987, Nucl. Acids Res. 15, 6131-6148), or a chimeric RNA-DNA analogue (Inoue, et al., 1987, FEBS Lett. 215, 327-330).

Oligonucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein, et al. (1988, Nucl. Acids Res. 16, 3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin, et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85, 7448-7451), etc.

While antisense nucleotides complementary to the target gene coding region sequence could be used, those complementary to the transcribed, untranslated region are most preferred. For example, antisense oligonucleotides having the following sequences can be utilized in accordance with the invention:

1) 5'-CTGTAGTTGA-3'

35

2) 5'-CTGTAGTTGATAAGTCG-3'

- 3) 5'-CTGTAGTTGATAAGTCGTCGGGCGA-3'
- 4) 5'-CTGTAGTTGATAAGTCGTCGGGCGATACTGGGGAGTCAATTCGGAGGGAA-3'
- 5) 5'-TGTGACCTTTTTTAACATCAACTTAA-3'
- 6) 5'-TGTGACCTTTTTTAACATCAACTTAATGGAGTGAGACAGTTGTCATTGAC-3'

Antisense molecules should be delivered to cells that express the target gene *in vivo*. A number of methods have been developed for delivering antisense DNA or RNA to cells; e.g., antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (e.g., antisense linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systemically.

However, it is often difficult to achieve intracellular concentrations of the antisense sufficient to suppress translation of endogenous mRNAs. Therefore a preferred approach utilizes a recombinant DNA construct in which the antisense oligonucleotide is placed under the control of a strong pol III or pol II promoter. The use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous target gene transcripts and thereby prevent translation of the target gene mRNA. For example, a vector can be introduced e.g., such that it is taken up by a cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the antisense RNA can be

by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Bernoist and Chambon, 1981, 5 Nature 290, 304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22, 787-797), the herpes thymidine kinase promoter (Wagner, et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78, 1441-1445), the regulatory sequences of the metallothionein 10 gene (Brinster, et al., 1982, Nature 296, 39-42), etc. Any type of plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct which can be introduced directly into the tissue site. Alternatively, viral vectors can be used that selectively infect the desired tissue, in 15 which case administration may be accomplished by another route (e.g., systemically).

Ribozyme molecules designed to catalytically cleave target gene mRNA transcripts can also be used to prevent translation of target gene mRNA and, therefore, expression of 20 target gene product. (See, e.g., PCT International Publication WO90/11364, published October 4, 1990; Sarver, et al., 1990, Science 247, 1222-1225).

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. (For a review, see 25 Rossi, 1994, Current Biology 4, 469-471). The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage event. The composition of ribozyme molecules must include one or more sequences 30 complementary to the target gene mRNA, and must include the well known catalytic sequence responsible for mRNA cleavage. For this sequence, see, e.g., U.S. Patent No. 5,093,246, which is incorporated herein by reference in its entirety.

While ribozymes that cleave mRNA at site specific 35 recognition sequences can be used to destroy target gene mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by

flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Myers, 1995, *Molecular Biology and Biotechnology: A Comprehensive Desk Reference*, VCH Publishers, New York, (see especially Figure 4, page 833) and in Haseloff and Gerlach, 1988, *Nature*, 334, 585-591, which is incorporated herein by reference in its entirety.

Preferably the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the target gene mRNA, i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

For example, hammerhead ribozymes having the following sequences can be utilized in accordance with the invention:

- 1) 5'-UUCGAAACCUAUGUCAAAAGCAGGNNNNCCUGAGNAGUCAGGGAGGCUU-3' which will cleave between nucleotides 48 and 49 in Figure 1.
- 2) 5'-AAAGGGAGGCUUAACUGAGGGGUCAAAGCAGGNNNNCCUGAGNAGUCAGCGCCUGCUGAAUAGUUGAUGUC -3' which will cleave between nucleotides 25 and 26 in Figure 1.

The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes") such as the one that occurs naturally in *Tetrahymena thermophila* (known as the IVS, or L-19 IVS RNA) and that has been extensively described by Thomas Cech and collaborators (Zaug, et al., 1984, *Science*, 224, 574-578; Zaug and Cech, 1986, *Science*, 231, 470-475; Zaug, et al., 1986, *Nature*, 324, 429-433; published International patent application No. WO 88/04300 by University Patents Inc.; Been and Cech, 1986, *Cell*, 47, 207-216). The Cech-type ribozymes have an eight base pair active site which hybridizes to a target RNA sequence whereafter cleavage of the target RNA takes place.

The invention encompasses those Cech-type ribozymes which target eight base-pair active site sequences that are present in the target gene.

As in the antisense approach, the ribozymes can be composed of modified oligonucleotides (e.g., for improved stability, targeting, etc.) and should be delivered to cells that express the target gene *in vivo*. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous target gene messages and inhibit translation. Because ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Endogenous target gene expression can also be reduced by inactivating or "knocking out" the target gene or its promoter using targeted homologous recombination (e.g., see Smithies, et al., 1985, Nature 317, 230-234; Thomas and Capecchi, 1987, Cell 51, 503-512; Thompson, et al., 1989, Cell 5, 313-321; each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional target gene (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous target gene (either the coding regions or regulatory regions of the target gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express the target gene *in vivo*. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the target gene. Such approaches are particularly suited in the agricultural field where modifications to ES (embryonic stem) cells can be used to generate animal offspring with an inactive target gene (e.g., see Thomas and Capecchi, 1987 and Thompson, 1989, *supra*). However this approach can be adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors.

Alternatively, endogenous target gene expression can be reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of the target gene (i.e., the target gene promoter and/or enhancers) to form
5 triple helical structures that prevent transcription of the target gene in target cells in the body. (See generally, Helene, 1991, *Anticancer Drug Des.*, 6(6), 569-584; Helene, et al., 1992, *Ann. N.Y. Acad. Sci.*, 660, 27-36; and Maher, 1992, *Bioassays* 14(12), 807-815).

10 Nucleic acid molecules to be used in triplex helix formation for the inhibition of transcription should be single stranded and composed of deoxynucleotides. The base composition of these oligonucleotides must be designed to promote triple helix formation via Hoogsteen base pairing
15 rules, which generally require sizeable stretches of either purines or pyrimidines to be present on one strand of a duplex. Nucleotide sequences may be pyrimidine-based, which will result in TAT and CGC triplets across the three associated strands of the resulting triple helix. The
20 pyrimidine-rich molecules provide base complementarity to a purine-rich region of a single strand of the duplex in a parallel orientation to that strand. In addition, nucleic acid molecules may be chosen that are purine-rich, for example, contain a stretch of G residues. These molecules
25 will form a triple helix with a DNA duplex that is rich in GC pairs, in which the majority of the purine residues are located on a single strand of the targeted duplex, resulting in GGC triplets across the three strands in the triplex.

Alternatively, the potential sequences that can be
30 targeted for triple helix formation may be increased by creating a so called "switchback" nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for
35 a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

In instances wherein the antisense, ribozyme, and/or triple helix molecules described herein are utilized to inhibit mutant gene expression, it is possible that the technique may so efficiently reduce or inhibit the transcription (triple helix) and/or translation (antisense, ribozyme) of mRNA produced by normal target gene alleles that the possibility may arise wherein the concentration of normal target gene product present may be lower than is necessary for a normal phenotype. In such cases, to ensure that substantially normal levels of target gene activity are maintained, therefore, nucleic acid molecules that encode and express target gene polypeptides exhibiting normal target gene activity may, be introduced into cells via gene therapy methods such as those described, below, in Section 5.9.2 that do not contain sequences susceptible to whatever antisense, ribozyme, or triple helix treatments are being utilized. Alternatively, in instances whereby the target gene encodes an extracellular protein, it may be preferable to co-administer normal target gene protein in order to maintain the requisite level of target gene activity.

Anti-sense RNA and DNA, ribozyme, and triple helix molecules of the invention may be prepared by any method known in the art for the synthesis of DNA and RNA molecules, as discussed above. These include techniques for chemically synthesizing oligodeoxyribonucleotides and oligoribonucleotides well known in the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

5.9.2. GENE REPLACEMENT THERAPY

With respect to an increase in the level of normal *fsh05* gene expression and/or *fsh05* gene product activity, *fsh05* gene nucleic acid sequences, described, above, in Section 5.1, can, for example, be utilized for the treatment of a *fsh05* disorder or a neuropsychiatric disorder, such as BAD. Such treatment can be administered, for example, in the form of gene replacement therapy. Specifically, one or more copies of a normal *fsh05* gene or a portion of the *fsh05* gene that directs the production of a *fsh05* gene product exhibiting normal *fsh05* gene function, may be inserted into the appropriate cells within a patient, using vectors that include, but are not limited to adenovirus, adeno-associated virus, and retrovirus vectors, in addition to other particles that introduce DNA into cells, such as liposomes.

Because the *fsh05* gene is expressed in the brain, such gene replacement therapy techniques should be capable delivering *fsh05* gene sequences to these cell types within patients. Thus, in one embodiment, techniques that are well known to those of skill in the art (see, e.g., PCT Publication No. WO89/10134, published April 25, 1988) can be used to enable *fsh05* gene sequences to cross the blood-brain barrier readily and to deliver the sequences to cells in the brain. With respect to delivery that is capable of crossing the blood-brain barrier, viral vectors such as, for example, those described above, are preferable.

In another embodiment, techniques for delivery involve direct administration of such *fsh05* gene sequences to the site of the cells in which the *fsh05* gene sequences are to be expressed.

Additional methods that may be utilized to increase the overall level of *fsh05* gene expression and/or *fsh05* gene product activity include the introduction of appropriate *fsh05*-expressing cells, preferably autologous cells, into a patient at positions and in numbers that are sufficient to ameliorate the symptoms of a *fsh05* disorder or a

neuropsychiatric disorder, such as BAD. Such cells may be either recombinant or non-recombinant.

Among the cells that can be administered to increase the overall level of *fsh05* gene expression in a patient are normal cells, preferably brain cells, that express the *fsh05* gene.

Alternatively, cells, preferably autologous cells, can be engineered to express *fsh05* gene sequences, and may then be introduced into a patient in positions appropriate for the amelioration of the symptoms of a *fsh05* disorder or a neuropsychiatric disorder, such as BAD. Alternately, cells that express an unimpaired *fsh05* gene and that are from a MHC matched individual can be utilized, and may include, for example, brain cells. The expression of the *fsh05* gene sequences is controlled by the appropriate gene regulatory sequences to allow such expression in the necessary cell types. Such gene regulatory sequences are well known to the skilled artisan. Such cell-based gene therapy techniques are well known to those skilled in the art, see, e.g., Anderson, U.S. Patent No. 5,399,349.

When the cells to be administered are non-autologous cells, they can be administered using well known techniques that prevent a host immune response against the introduced cells from developing. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Additionally, compounds, such as those identified via techniques such as those described, above, in Section 5.8, that are capable of modulating *fsh05* gene product activity can be administered using standard techniques that are well known to those of skill in the art. In instances in which the compounds to be administered are to involve an interaction with brain cells, the administration techniques should include well known ones that allow for a crossing of the blood-brain barrier.

5.10. PHARMACEUTICAL PREPARATIONS AND METHODS OF ADMINISTRATION

The compounds that are determined to affect *fsh05* gene expression or gene product activity can be administered
5 to a patient at therapeutically effective doses to treat or ameliorate a *fsh05* disorder or a neuropsychiatric disorder, such as BAD. A therapeutically effective dose refers to that amount of the compound sufficient to result in amelioration of symptoms of such a disorder.

10

5.10.1. EFFECTIVE DOSE

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining
15 the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds that exhibit large therapeutic
20 indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

25 The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may
30 vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal
35 models to achieve a circulating plasma concentration range that includes the IC₅₀ (i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms)

as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

5

5.10.2. FORMULATIONS AND USE

Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers
10 or excipients.

Thus, the compounds and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal
15 administration.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g.,
20 pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch
25 glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water
30 or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin
35 or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or

sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

Preparations for oral administration may be
5 suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

10 For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane,
15 trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be
20 formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be
25 presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain
30 dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g.,
35 containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or 5 intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly 10 soluble salt.

The compositions may, if desired, be presented in a pack or dispenser device that may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister 15 pack. The pack or dispenser device may be accompanied by instructions for administration.

20

25

30

35

6. EXAMPLE: IDENTIFICATION AND CLONING OF THE fsh05 GENE

In the Example presented in this Section, studies are described that, first, define an interval approximately 500 kb on the long arm of human chromosome 18 within which a region associated with a neuropsychiatric disorder is located and, second, identify and clone a novel gene, referred to herein as *fsh05*, which lies within this region and which can be involved in neuropsychiatric disorders.

10

6.1. MATERIALS AND METHODS

Linkage Disequilibrium. Linkage disequilibrium (LD) studies were performed using DNA from a population sample of neuropsychiatric disorder (BP-I) patients. The population sample and LD techniques were as described in Friemer et al., 1996, Nature Genetics 12:436-441. The present LD study took advantage of the additional physical markers identified via the physical mapping techniques described below.

Yeast artificial chromosome (YAC) mapping. For physical mapping, yeast artificial chromosomes (YACs) containing human sequences were mapped to the region being analyzed based on publicly available maps (Cohen et al., 1993, C.R. Acad. Sci. 316, 1484-1488). The YACs were then ordered and contig reconstructed by performing standard short tag sequence (STS)-content mapping with microsatellite markers and non-polymorphic STSs available from databases that surround the genetically defined candidate region.

Bacterial artificial chromosome (BAC) mapping. The STSs from the region were used to screen a human BAC library (Research Genetics, Huntsville, AL). The ends of the BACs were cloned or directly sequenced. The end sequences were used to amplify the next overlapping BACs. From each BAC, additional microsatellites were identified. Specifically, random sheared libraries were prepared from overlapping BACs within the defined genetic interval. BAC DNA was sheared with a nebulizer (CIS-US Inc., Bedford, MA). Fragments in the size range of 600 to 1,000 bp were utilized for the

sublibrary production. Microsatellite sequences from the sublibraries were identified by corresponding microsatellite probes. Sequences around such repeats were obtained to enable development of PCR primers for genomic DNA.

5 Radiation hybrid (RH) mapping. Standard RH mapping techniques were applied to a Stanford G3 RH mapping panel (Research Genetics, Huntsville, AL) to order all microsatellite markers and non-polymorphic STSs in the region being analyzed.

10 Sample sequencing. Random sheared libraries were made from all the BACs within the defined genetic region. Approximately 6,000 subclones within the approximately 500 kb region were sequenced with vector primers in order to achieve a 6-fold sequence coverage of the region. All sequences were
15 processed through an automated sequence analysis pipeline that assessed quality, removed vector sequences and masked repetitive sequences. The resulting sequences were then compared to public DNA and protein databases using BLAST algorithms (Altschul, et al., 1990, J. Molec. Biol., 215,
20 403-410).

cDNA selection. cDNA selection was used as an additional method for gene identification of transcribed sequences over large regions of the genome. Through a combination of characterizations including physical mapping
25 and RNA hybridization, the selected cDNAs were arranged into transcription units. The cDNA selection technique was carried out as described by Rommens, et al. (1994, in *Identification of Transcribed Sequences*, Hochgeschwender and Gardiner, eds., Plenum Press, New York, pp. 65-79).

30 Transcription mapping. The combination of sample sequencing and cDNA selection were arranged into tentative transcription units which provided the framework for a detailed transcription map of the genomic region of interest.

cDNA library. A human fetal brain cDNA library was
35 purchased Clontech (Palo Alto, CA) and screened according to manufacturer's recommendations.

Northern analysis. Standard Northern analysis techniques were utilized in probing human and fetal multiple tissue Northern blots purchased from Clontech (Palo Alto, CA). Blots were hybridized to a 777 bp probe, which was 5 derived by PCR from a *fsh05* cDNA sequence.

6.2. RESULTS

Genetic regions involved in bipolar affective disorder (BAD) human genes had previously been reported to 10 map to portions of the long (18q) and short (18p) arms of human chromosome 18, including a broad 18q genetic region of about 6-7 cM between markers D18S469 and D18S554 (U.S. Provisional Applications Serial Nos. 60/014,498 and 60/023,438, filed on March 28, 1996 and August 23, 1996, 15 respectively, the entire contents of each of which are incorporated herein by reference; Freimer, et al., 1996, *Neuropsychiat. Genet.* 67, 254-263; Freimer, et al., 1996, *Nature Genetics* 12, 436-441), the entire contents of each of which are incorporated herein by reference.

20 Prior to attempting to identify gene sequences, studies were performed to further narrow the neuropsychiatric disorder region. Specifically, a linkage disequilibrium (LD) analysis was performed using population samples and techniques as described in Section 6.1, above, which took 25 advantage of the additional physical markers identified via the physical mapping techniques described below.

In order to provide the precise order of genetic markers necessary for linkage and LD mapping, and to guide new microsatellite marker development for finer mapping, a 30 high resolution physical map of the 18q23 candidate region was developed using YAC, BAC and RH techniques.

For such physical mapping, first, YACs were mapped to the chromosome 18 region being analyzed. Using the mapped YAC contig as a framework, the region from publicly available 35 markers D18S1161 and D18S554, which spans most of the D18S469-D18S554 region described above, was also mapped and contiged with BACs. Sublibraries from the contiged BACs were

constructed, from which microsatellite marker sequences were identified and sequenced.

To ensure development of an accurate physical map, the radiation hybrid (RH) mapping technique was independently
5 applied to the region being analyzed. RH was used to order all microsatellite markers and non-polymorphic STSS in the region. Thus, the high resolution physical map ultimately constructed was obtained using data from RH mapping and STS-content mapping.

10 The new markers identified via physical mapping were typed in an LD analysis of samples collected from families affected with bipolar affective disorder. One interpretation of the results of this LD analysis narrows
15 down the chromosome 18 long arm region within which a gene involved in neuropsychiatric disorders lies to an interval of about 500 kb between the publicly available markers D18S1121 and D18S380.

The BAC clones within the newly identified 500 kb neuropsychiatric disorder region were further analyzed to
20 identify specific genes within the region. A combination of sample sequencing, cDNA selection and transcription mapping analyses were combined to arrange sequences into tentative transcription units, that is, tentatively delineating the coding sequences of genes within this genomic region of
25 interest.

One of the transcription units identified was termed *fsh05*. The corresponding *fsh05* gene can, therefore, can be involved in neuropsychiatric disorders.

fsh05 cDNA clones were isolated through screening and
30 random sequencing of a human fetal brain cDNA library. Among the cDNA clones identified were FSH5-1 (ATCC accession No. 98317) and FSH5-2 (ATCC accession No. 98318). Upon further analysis of genomic sequences, it was determined that the full length *fsh05* gene sequence is contained within BAC54
35 (Identification Reference EpHS996, ATCC Accession No. 98363).

fsh05 nucleotide and amino acid sequences are shown in Figure 1. The *fsh05* gene product sequence depicted

in Figure 1 exhibits some amino acid sequence similarity with two known genes identified from other distantly related species. First, the depicted portion of the *fsh05* gene product exhibits approximately 45% amino acid sequence
 5 similarity with a 295 amino acid residue portion of P36, a possible *Leishmania amazonensis* quinone oxidoreductase (Liu and Chang, 1994, Mol. Biochem. Parasitol. 66, 201-120). The depicted portion of the *fsh05* gene product also exhibits approximately 45% amino acid sequence similarity with a 292
 10 amino acid portion of ARP, an *Arabidopsis thaliana* NADPH oxidoreductase homolog (Babiychuk, et al., 1995, J. Biol. Chem. 270, 26224-26231). In addition, a portion (primarily non-coding) of the depicted *fsh05* nucleotide sequence, was found to exhibit similarity to EST U55988.

15 Northern analysis was used to examine *fsh05* expression. The Northern analysis revealed that *fsh05* appears to be expressed in adult heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, and in fetal brain, lung, liver, and kidney. Bands of 6 kb and 4 kb were
 20 seen in all the above tissues.

7. DEPOSIT OF MICROORGANISMS

The following microorganisms were deposited with the American Type Culture Collection (ATCC), Rockville, Maryland,
 25 on the date indicated and assigned the indicated accession number:

| | <u>Microorganism</u> | <u>ATCC Accession No.</u> | <u>Date of Deposit</u> |
|----|----------------------|---------------------------|------------------------|
| | FSH5-1 | ATCC 98317 | February 7, 1997 |
| | FSH5-2 | ATCC 98318 | February 7, 1997 |
| 30 | EpHS996 | ATCC 98363 | March 19, 1997 |

The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as single illustrations of individual aspects of the
 35 invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown

and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

5

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be
10 incorporated by reference.


15

20

25

30

35

| MICROORGANISMS | |
|--|--|
| Optional Sheet in connection with the microorganism referred to on page <u>74</u> , lines <u>22-30</u> of the description * | |
| A. IDENTIFICATION OF DEPOSIT * | |
| Further deposits are identified on an additional sheet * | |
| Name of depositary institution * | |
| American Type Culture Collection | |
| Address of depositary institution (including postal code and country) * | |
| 12301 Parklawn Drive Rockville, MD 20852 US | |
| Date of deposit * <u>February 7, 1997</u> Accession Number * <u>98317</u> | |
| B. ADDITIONAL INDICATIONS * (leave blank if not applicable). This information is continued on a separate attached sheet | |
| | |
| C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE * (if the indications are not all designated States) | |
| | |
| D. SEPARATE FURNISHING OF INDICATIONS * (leave blank if not applicable) | |
| The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit") | |
| | |
| E. <input checked="" type="checkbox"/> This sheet was received with the International application when filed (to be checked by the receiving Office) | |
|  _____ (Authorized Officer) | |
| <input type="checkbox"/> The date of receipt (from the applicant) by the International Bureau * | |
| was _____ | |
| _____ | |
| (Authorized Officer) | |

Form PCT/RO/134 (January 1981)

International Application No: PCT/ /

Form PCT/RO/134 (cont.)

American Type Culture Collection

12301 Parklawn Drive
Rockville, MD 20852
US

Accession No.

Date of Deposit

98318

February 7, 1997

98363

March 19, 1997

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising;
 - a. a nucleic acid molecule encoding a polypeptide
5 comprising the amino acid sequence shown in
FIG. 1 (SEQ. ID NO. 2); or
 - b. a nucleic acid molecule encoding a polypeptide
comprising the amino acid sequence encoded by
the nucleic acid insert of the clone contained
10 in ATCC accession No. 98317 or in ATCC
accession No. 98318.

2. The isolated nucleic acid molecule of Claim 1
wherein the nucleic acid molecule contains the nucleotide
15 sequence shown in FIG. 1 (SEQ. ID NO. 1).

3. An isolated nucleic acid molecule which
hybridizes to the complement of the nucleic acid molecule of
Claim 1 and encodes a polypeptide involved in a
20 neuropsychiatric disorder.

4. The isolated nucleic acid molecule of Claim 3
wherein the neuropsychiatric disorder is schizophrenia,
attention deficit disorder, a schizoaffective disorder, a
25 bipolar affective disorder or a unipolar affective disorder.

5. The isolated nucleic acid molecule of Claim 4
wherein the bipolar affective disorder is severe bipolar
affective (mood) disorder, bipolar affective (mood) disorder
30 with hypomania and major depression, or schizoaffective
disorder manic type.

6. The isolated nucleic acid molecule of Claim 4
wherein the unipolar affective disorder is unipolar major
35 depressive disorder.

7. An isolated nucleic acid molecule which hybridizes under stringent conditions to the complement of the nucleic acid molecule of Claim 1.

5 8. The isolated nucleic acid molecule of Claim 3 or 7 wherein the nucleic acid molecule encodes a naturally occurring polypeptide.

9. A nucleotide vector containing the nucleotide
10 sequence of Claim 1, 3 or 7.

10. An expression vector containing the nucleotide sequence of Claim 1, 3 or 7 in operative association with a nucleotide regulatory sequence that controls expression of
15 the nucleotide sequence in a host cell.

11. The expression vector of Claim 10, wherein said regulatory element is selected from the group consisting of the cytomegalovirus hCMV immediate early gene, the early
20 or late promoters of SV40 adenovirus, the *lac* system, the *trp* system, the *TAC* system, the *TRC* system, the major operator and promoter regions of phage A, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast
25 α -mating factors.

12. A genetically engineered host cell that contains the nucleotide sequence of Claim 1, 3 or 7.

30 13. A genetically engineered host cell that contains the nucleotide sequence of Claim 1, 3 or 7 in operative association with a nucleotide regulatory sequence that controls expression of the nucleotide sequence in the host cell.

35

14. An isolated gene product comprising:

- a. the amino acid sequence shown in FIG. 1 (SEQ. ID NO. 2); or
- b. the amino acid sequence encoded by the nucleic acid insert of the clone contained in ATCC accession No. 98317 or ATCC accession No. 98318.
- 5
15. An isolated gene product encoded by the nucleic acid molecule of Claim 3 or 7.
- 10
16. An antibody that immunospecifically binds the gene product of Claim 14.
17. An antibody that immunospecifically binds the 15 gene product of Claim 15.
18. A method for diagnosing a neuropsychiatric disorder in a mammal, comprising: measuring *fsh05* gene expression in a patient sample.
- 20
19. The method of Claim 18 wherein the neuropsychiatric disorder is schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar disorder.
- 25
20. The method of Claim 19 wherein the bipolar affective disorder is severe bipolar affective (mood) disorder, bipolar affective (mood) disorder with hypomania and major depression, or schizoaffective disorder manic type.
- 30
21. The method of Claim 19 wherein the unipolar affective disorder is unipolar major depressive disorder.
22. The method of Claim 18 in which expression is 35 measured by detecting *fsh05* mRNA transcripts.

23. The method of Claim 18 in which expression is measured by detecting *fsh05* gene product.

24. A method for diagnosing a *fsh05* disorder in a mammal, comprising: measuring *fsh05* gene expression in a patient sample.

25. The method of Claim 24 in which expression is measured by detecting *fsh05* mRNA transcripts.

10

26. The method of Claim 24 in which expression is measured by detecting *fsh05* gene product.

27. A method for diagnosing a neuropsychiatric disorder in a mammal, comprising: detecting a *fsh05* gene mutation contained in the genome of the mammal.

28. The method of Claim 27 wherein the neuropsychiatric disorder is schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar disorder.

29. The method of Claim 28 wherein the bipolar affective disorder is severe bipolar affective (mood) disorder, bipolar affective (mood) disorder with hypomania and major depression, or schizoaffective disorder manic type.

30. The method of Claim 28 wherein the unipolar affective disorder is unipolar major depressive disorder.

30

31. A method for diagnosing a *fsh05* disorder in a mammal, comprising: detecting a *fsh05* gene mutation contained in the genome of the mammal.

32. A method for identifying a compound capable of modulating a *fsh05* activity, comprising:

35

- a. contacting a compound to a cell that expresses a *fsh05* gene;
- b. measuring the level of *fsh05* gene expression in the cell; and
- 5 c. comparing the level obtained in (b) to *fsh05* gene expression level obtained in the absence of the compound;

such that if the level obtained in (b) differs from that obtained in the absence of the compound, a compound capable
10 of modulating a *fsh05* activity has been identified.

33. The method of Claim 32 wherein the compound increases the level of *fsh05* gene expression.

15 34. The method of Claim 32 wherein the compound decreases the level of *fsh05* gene expression.

35. The method of Claim 32 in which expression of the *fsh05* gene is detected by measuring *fsh05* mRNA
20 transcripts.

36. The method of Claim 32 in which expression of the *fsh05* gene is detected by measuring *fsh05* gene product.

25 37. The method of Claim 32 wherein the compound is a small organic molecule.

38. A method for identifying a compound capable of treating a neuropsychiatric disorder, comprising:

- 30 a. contacting a compound to a cell that expresses a *fsh05* gene;
- b. measuring the level of *fsh05* gene expression in the cell; and
- 35 c. comparing the level obtained in (b) to *fsh05* gene expression level obtained in the absence of the compound;

such that if the level obtained in (b) differs from that obtained in the absence of the compound, a compound capable of treating a neuropsychiatric disorder has been identified.

- 5 39. The method of Claim 38 wherein the neuropsychiatric disorder is schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar disorder.
- 10 40. The method of Claim 39 wherein the bipolar affective disorder is severe bipolar affective (mood) disorder, bipolar affective (mood) disorder with hypomania and major depression, or schizoaffective disorder manic type.
- 15 41. The method of Claim 39 wherein the unipolar affective disorder is unipolar major depressive disorder.
42. The method of Claim 38 wherein the compound increases the level of *fsh05* gene expression.
- 20 43. The method of Claim 38 wherein the compound decreases the level of *fsh05* gene expression.
44. The method of Claim 38 in which expression of
25 the *fsh05* gene is detected by measuring *fsh05* mRNA transcripts.
45. The method of Claim 38 in which expression of the *fsh05* gene is detected by measuring *fsh05* gene product.
- 30 46. The method of Claim 38 in which the compound is a small organic molecule.
47. A method for treating a neuropsychiatric
35 disorder in a mammal comprising administering to the mammal a compound to the mammal that modulates the synthesis, expression or activity of a mammalian *fsh05* gene or *fsh05*

gene product so that symptoms of the disorder are ameliorated.

48. The method of Claim 47 wherein the
5 neuropsychiatric disorder is schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar disorder.

49. The method of Claim 48 wherein the bipolar
10 affective disorder is severe bipolar affective (mood) disorder, bipolar affective (mood) disorder with hypomania and major depression, or schizoaffective disorder manic type.

50. The method of Claim 47 wherein the unipolar
15 affective disorder is unipolar major depressive disorder.

51. The method of Claim 47 wherein the compound increases the synthesis, expression or activity of a mammalian *fsh05* gene or *fsh05* gene product.
20

52. The method of Claim 51 wherein the compound comprises the nucleic acid molecule of Claim 1, 3 or 7.

53. The method of Claim 51 wherein the compound is
25 a small organic molecule.

54. The method of Claim 47 wherein the compound decreases the synthesis, expression or activity of a mammalian *fsh05* gene or *fsh05* gene product.
30

55. The method of Claim 54 wherein the compound provides an antisense or ribozyme molecule that blocks translation of *fsh05* mRNAs.

56. The method of Claim 54 wherein the compound provides a nucleic acid molecule that is complementary to a

fsh05 gene and blocks *fsh05* transcription via triple helix formation.

57. The method of Claim 54 wherein the compound is
5 a small organic molecule.

58. A method for treating a *fsh05* disorder in a mammal comprising administering to the mammal a compound to the mammal that modulates the synthesis, expression or
10 activity of a mammalian *fsh05* gene or *fsh05* gene product so that symptoms of the disorder are ameliorated.

59. The method of Claim 58 wherein the compound increases the synthesis, expression or activity of a
15 mammalian *fsh05* gene or *fsh05* gene product.

60. The method of Claim 59 wherein the compound comprises the nucleic acid molecule of Claim 1, 3 or 7.

20 61. The method of Claim 59 wherein the compound is a small organic molecule.

62. The method of Claim 58 wherein the compound decreases the synthesis, expression or activity of a
25 mammalian *fsh05* gene or *fsh05* gene product.

63. The method of Claim 62 wherein the compound provides an antisense or ribozyme molecule that blocks translation of *fsh05* mRNAs.
30

64. The method of Claim 62 wherein the compound provides a nucleic acid molecule that is complementary to a *fsh05* gene and blocks *fsh05* transcription via triple helix formation.
35

65. The method of Claim 62 wherein the compound is a small organic molecule.

66. A method of treating a neuropsychiatric disorder resulting from a mutation in a *fsh05* gene, in a mammal, comprising supplying the mammal with a nucleic acid molecule that encodes an unimpaired *fsh05* gene product such
5 that an unimpaired *fsh05* gene product is expressed and symptoms of the disorder are ameliorated.

67. The method of Claim 66 wherein the neuropsychiatric disorder is schizophrenia, attention deficit
10 disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar disorder.

68. The method of Claim 67 wherein the bipolar affective disorder is severe bipolar affective (mood)
15 disorder, bipolar affective (mood) disorder with hypomania and major depression, or schizoaffective disorder manic type.

69. The method of Claim 67 wherein the unipolar affective disorder is unipolar major depressive disorder.
20

70. The method of Claim 66 in which a nucleic acid molecule encoding the unimpaired *fsh05* protein, contained in a pharmaceutically acceptable carrier, is administered to the mammal.
25

71. The method of Claim 70 in which the carrier is a DNA vector, a viral vector, a liposome or lipofectin.

72. The method of Claim 66 in which the nucleic
30 acid encoding an unimpaired *fsh05* protein is introduced into the brain of the mammal.

73. A method of treating a *fsh05* disorder resulting from a mutation in a *fsh05* gene in a mammal,
35 comprising supplying the mammal with a nucleic acid molecule that encodes an unimpaired *fsh05* gene product such that an

unimpaired *fsh05* gene product is expressed and symptoms of the disorder are ameliorated.

74. The method of Claim 73 in which a nucleic acid molecule encoding an unimpaired *fsh05* protein, contained in a pharmaceutically acceptable carrier, is administered to the mammal.

75. The method of Claim 74 in which the carrier is a DNA vector, a viral vector, a liposome or lipofectin.

76. A method of treating a neuropsychiatric disorder resulting from a mutation in a *fsh05* gene in a mammal, comprising supplying the mammal with a cell comprising a nucleic acid molecule that encodes an unimpaired *fsh05* gene product such that the cell expresses unimpaired *fsh05* gene product and symptoms of the neuropsychiatric disorder are ameliorated.

77. The method of Claim 76 wherein the neuropsychiatric disorder is schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar disorder.

78. The method of Claim 77 wherein the bipolar affective disorder is severe bipolar affective (mood) disorder, bipolar affective (mood) disorder with hypomania and major depression, or schizoaffective disorder manic type.

79. The method of Claim 77 wherein the unipolar affective disorder is unipolar major depressive disorder.

80. The method of Claim 76 in which the cell is engineered *ex vivo* to express an unimpaired *fsh05* protein.

81. The method of Claim 76 in which the cell is contained in a carrier.

82. The method of Claim 76 in which a nucleic acid molecule encoding an unimpaired *fsh05* protein, contained in a pharmaceutically acceptable carrier, is administered to the mammal.

5

83. The method of Claim 82 in which the carrier is a DNA vector, a viral vector, a liposome or lipofectin.

84. A method of treating a *fsh05* disorder
10 resulting from a mutation in a *fsh05* gene in a mammal, comprising supplying the mammal with a cell comprising a nucleic acid molecule that encodes an unimpaired *fsh05* gene product such that the cell expresses unimpaired *fsh05* gene product and symptoms of the disorder are ameliorated.

15

85. The method of Claim 84 in which the cell is engineered *ex vivo* to express an unimpaired *fsh05* protein.

86. The method of Claim 84 in which the cell is
20 contained in a carrier.

87. The method of Claim 84 in which a nucleic acid molecule encoding an unimpaired *fsh05* protein, contained in a pharmaceutically acceptable carrier, is administered to the
25 mammal.

88. The method of Claim 84 in which the carrier is a DNA vector, a viral vector, a liposome or lipofectin.

30 89. A method of mapping a human chromosome 18q region spanning DS18S1121 and 18SS30 chromosomal markers comprising identifying, aligning and detecting *fsh05* polymorphisms within the 18q region.

35

1/4

D I N Y S A G R Y D P S V K P P F D I G 20
 GAC ATC AAC TAT TCA GCA GGC CGC TAT GAC CCC TCA GTT AAG CCT CCC TTT GAC ATA GGT 60

 F E G I G E V A L G L S A S A R Y T V 40
 TTC GAA GGC ATT GGG GAG GTG GGC CTA GGC CTC TCT GCT AGT GCC AGA TAC ACA GTT 120

 G Q A V A Y M A P G S F A E Y T V V P A 60
 GGC CAA GCT GTG GCT TAC ATG GCA CCT GGT TCT TTT GCT GAG TAC ACA GTT GTG CCT GCC 180

 S I A T P V P S V K P E Y L T L L V S G 80
 AGC ATT GCA ACT CCA GTG CCC TCA GTG AAA CCC GAG TAT CTT ACC CTG CTG GTA AGT GGC 240

 T T A Y I S L K E L G G L S E G K K V L 100
 ACC ACC GCA TAC ATC AGC CTG AAA GAG CTC GGA GGA CTG TCG GAA GGG AAA AAA GTT TTG 300

 V T A A A G G T G Q F A M Q L S K K A K 120
 GTG ACA GCA GCA GCT GGG GGA ACG GGC CAG TTT GCC ATG CAG CTT TCA AAG AAG GCA AAG 360

 C H V I G T C S S D E R K A F L K S L G 140
 TGC CAT GTA ATT GGA ACC TGC TCT TCT GAT GAA AAG TCT GCT TTT CTG AAA TCT CTT GGC 420

 C D R P I N Y K T E P V G T V L K Q E Y 160
 TGT GAT CGT CCT ATC AAC TAT AAA ACT GAA CCC GTA GGT ACC GTC CTT AAG CAG GAG TAC 480

 P E G V D V V Y E S V G G A M F D L A V 180
 CCT GAA GGT GTC GAT GTG GTC TAT GAA TCT GTT GGG GGA GCC ATG TTT GAC TTG GCT GTA 540

FIG.1A

```

D  A  L  A  T  K  G  R  L  I  V  I  G  F  I  S  G  Y  Q  T  200
GAC  GCC  CTG  GCT  ACG  AAA  GGG  CGC  TTG  ATA  GTA  ATA  GGG  TTT  ATC  TCT  GGC  TAC  CAA  ACT  600

P  T  G  L  S  P  V  K  A  G  T  L  P  A  K  L  L  K  K  S  220
CCT  ACT  GGC  CTT  TCG  CCT  GTG  AAA  GCA  GGA  ACA  TTG  CCA  GCC  AAA  CTG  CTC  AAG  AAA  TCT  660

A  S  V  Q  G  F  L  N  H  Y  L  S  K  Y  Q  A  A  M  S  240
GCC  AGC  GTA  CAG  GGC  TTC  TTC  CTG  AAC  CAT  TAC  CTT  TCT  AAG  TAT  CAA  GCA  GCC  ATG  AGC  720

H  L  L  E  M  C  V  S  G  D  L  V  C  E  V  D  L  G  D  L  260
CAC  TTG  CTC  GAG  ATG  TGT  GTG  AGC  GGA  GAC  CTG  GTT  TGT  GAG  GTG  GAC  CTT  GGA  GAT  CTG  780

S  P  E  G  R  F  T  G  L  E  S  I  F  R  A  V  N  Y  M  Y  280
TCT  CCA  GAG  GGC  AGG  TTT  ACT  GGC  CTG  GAG  TCC  ATA  TTC  CGT  GCT  AAT  TAT  ATG  TAC  840

M  G  K  N  T  G  K  I  V  V  E  L  P  H  S  V  N  S  K  L  300
ATG  GGG  AAA  AAC  ACT  GGA  AAA  ATT  GIA  GTT  GAA  TTA  CCT  CAC  TCT  GTC  AAC  AGT  AAG  CTG  900

*
TAA  AACAGAACAAATGACATAAATCAAGGGAGAAAGAAAATGGGCACITTTATGTCTCAGAA
TTACTCAAATCAATTTATTTTAGTTGGTAATGGATATAATAATTTCTTAAACAAAAGTA
AGGTGTTAATGAATAGGTCTCTCCTTCTCTCCCTCCTCCTCCTCCTCCCTGGGGAAGA
AAAAAATGTGCTAATAAAAACCTCGTGCATAGGTAAGAGGGAAAACGCTTACATTCAAT
TCTTTAGTCATGGATGGTTCGTTCCAGATGTTATGTCCAGGAACCTAAATTCATTC
TGATGCCAGATCTGATCGAGTCAGTATGTCTTCCAGTTCAGTTCAGATTTTAAAATCAGTTT
TGAAAAGTGGTCCCGACTCTTTGCTTTGGGAGAATTTGGTCTTATGCTCATAAGCAGTT
CATGAGTGACAAGTGTAGCAAAAAGCCAGCCATATATTTTTCAGAAATCTATATCCTCAGGAA

```

FIG. 1B

1440 ATGGTCCTTTTTTTCTATAAATCACCACCAACTATCTAAATGGACATTTGGGGGAAT
 1500 TCCCTCCCAAAATTTGATTTTIGTATTAGAAAAATGATCCGTGAACACACAGATGTGTTTTG
 1560 AAGAAGTAGCAGTAATGGCTTTTATCTACCATCAACCTGATAAGGCACATGTGAAATGG
 1620 AAATGTTCTTTCCCTCGAAGCAGCAAAATTAATGTTGAAAACTTACATAGACAGAAAAGT
 1680 AGGTTTTGGAAAGGAAACCCACAGAGATTAGGGGACTTAAATTAATATAGGCACAGGA
 1740 AAGAGAAAAGTGTGGCTCCATTTCTCAGTGGGGTACCACAAACACGGGCCCCAGGAGG
 1800 GAAGCGTGTCTAGGCACACGGCAAGGCTTAGTAACAGCATGCTACACTGCTCGAGGTA
 1860 CGGTATGTCCCATCGCCCTGTGCACCGTAGAGACCTCAGTCACTCAAGGAAGAAATACAT
 1920 TTGCTTCTCTTAGAGGCGTTGAACTAGAGCTATGCGTTACCTCTGATCTGGAACAG
 1980 AATAGCAGCCACTCATCTGCAATCCCATTTTTCTCCACGTTCTCGTGGGAATGAGA
 2040 TGCTCCTTGGCACAATAGCCGTGATGCCACATTGACCCACTGACCACACAGGAAAAGCA
 2100 GCGAAACCTGCACCCCTCTCTTGAGTCCAGCCGTGGCTCACTGGCTTCCCTCTTAACC
 2160 TTTAGTGGCTGAAGACTGCTGCCGCTGTCCCGTTGCCGTGAACCCCATGGGCCCGTT
 2220 CTGATGAAGGTGAAGCCACCAGATTAATTTCAAAGTCTTAGGTTTCGGTGTATCTAA
 2280 CCTGCTCAGTAAATAGCCGCAATTAAGATGCTCTAGGAAATTTGGGGACTGTATTTA
 2340 ATTTTTCTTCCCTCCATCTGAGGAGCAGAACTCTACTGTGAAATAGCTGTAGTATCT
 2400 ATTTTACAGATTTACTCATTTTCAGGTACCTAATGTAGCTGTAGCATGCATGCACACAA
 2460 TTCAAATTAATGTTAAATGGAACCAAAATAATGGCTTCACTGAAATGTTATGGCTGCACATG
 2520 AAGGAAATGTCACGGTAAATAGCTGCCAAATATGGATCATGCCGAAGTGTCAACAATG
 2580 CACTAAAGACAAAATAGCCACTAGAGGCTATGCCACTGTGACCGCTTTGAGTTATGAAGA
 2640 AGGGTAGCGGCTGATGCGAGGCTCTTTGTGCTCATTATAGCAAAAGGTTACTGTGTC
 2700 AGGGGACTAGGAAAACCCGTCAGTGTGGTGTAGTTATTCATCCATCCCTTTCAGAC
 2760 CTAAAGCCACAGCCACACGGAAAGAGACTTGCCTCACTTTTACATTCACAAACAAC
 2820 AAAGGAGGGGGAGCAGGTTTTATGAATGTAACGTGCACAGGAAATGACTGGTAAATGGA
 2880 AAAAAATGTTGTAATAAAAAATACTAATCAAAGAAATATTAATTAATTAACATAGTCTATG
 2940 TCCAAAAGGCTTAGTTGCTTCTATGCAGATAGATGTGAAATNTAAGCAGTAATGTAC
 3000 TTTCTCCCTTGTAAAGACTTGGGGAGTAAGGACATACCAACTAAATTTGCTTCTTCGAA
 3060 ACTGAAGTGAGTCCCAGTTTGTTCATTTTAAATGGGAGGGTAAATAAGATGAAAGACCAA

FIG. 1C

3120 CATTTAACTGATGGATCCCTTAAGCTACAGAATAGAAATTTATTGTGTTTTGAGGGAAT
3180 ATACTAAATGCAGCTATGTAAAAATAAAATCAAACGCCAGGATTAATAATAAAATATAA
3240 TCTGAAAACCTCATGTTCTCTCTTCCCAAACTAAGAAAGTGCATGCTGTTTTTC
3300 ACTTATCTTAGAAAACAAGCATGAAAGATTCCTCCCATTCAGATAATGCCAAAATATG
3360 TTTAACTTTTTTTTTATTCTTTTGAAAAATGATTTGTAAATTGAGGGTCATAGTTCAGCA
3420 TCAGTTTCATCTCTGGGATTAATGTTCAAGACCAGCCTTAATGGGAGGTGAAACGGTA
3480 CGATGGTCTCAACACCTTCTTGTGAACGTAAATACATAACAAAAAGTACATCCATAA
3540 TTCAGGGCAATTGTCAGTCTTTTTAGAGAAGGGGCCAGGGTGGAAACAATCCCAGTGAGTA
3600 AATATTTCTCAGCGTGGACTTCTCTGCAATGTCGGGCTTAGGGTCACCCAGCCGGGCAGGG
3660 TGGAAGGAGCTTGCTTCTTTGAGAAAACCAAGGAGTCCCAGTGATCTGTTACCATTTGGTT
3720 ATGACTTCTAAAGAGCCAAA TGCTATTCCTTCAAGCCTGTTTTGCAGGCAGAAAA TACCA
3780 GCAGTGTCAATTTAGGGGTTCCTTTGATGATGACTACTGCTGTTAACTGACCTCAGCAAAA
3794 AAAAAAAAAAAAAA

FIG. 1D

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/06208

| A. CLASSIFICATION OF SUBJECT MATTER | | |
|--|---|--|
| IPC(6) :Please See Extra Sheet. US CL :Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC | | |
| B. FIELDS SEARCHED | | |
| Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/93.1; 435/6, 7.21, 243, 252.3, 320.1, 325; 514/44; 530/350, 387.1; 536/23.1, 23.5, 24.5, 24.31 | | |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched | | |
| Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet. | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | |
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| A | LEWIN, Benjamin. Genes IV. Oxford: Oxford University Press. 1990, page 805. | 1-89 |
| A | EWALD et al. Susceptibility loci for bipolar affective disorder on chromosome 18? A review and a study of Danish families. Psychiatric Genetics. 1997, Vol. 7, pages 1-12, see entire document. | 1-89 |
| A | MACKINNON et al. Genetics of manic depressive illness. Annu. Rev. Neurosci. 1997, Vol. 20, pages 355-373, see entire document. | 1-89 |
| A | BARON, M. Genetic linkage and bipolar affective disorder: progress and pitfalls. Molecular Psychiatry. 1997, Vol. 2, pages 200-210, see entire document. | 1-89 |
| <input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex. | | |
| * Special categories of cited documents: | | * later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| *A* document defining the general state of the art which is not considered to be of particular relevance | | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| *B* earlier document published on or after the international filing date | | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | | *Z* document member of the same patent family |
| *O* document referring to an oral disclosure, use, exhibition or other means | | |
| *P* document published prior to the international filing date but later than the priority date claimed | | |
| Date of the actual completion of the international search 03 MAY 1998 | Date of mailing of the international search report 23 JUN 1998 | |
| Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 | Authorized officer PATRICIA A. DUFFY <i>[Signature]</i> Telephone No. (703) 308-0196 | |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/06208

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 38/00, 48/00; C07H 21/02, 21/04; C07K 14/00; C12N 1/20, 15/00, 15/11, 15/63, 15/85, 15/86

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/93.1; 435/6, 7.21, 243, 252.3, 320.1, 325; 514/44; 530/350, 387.1; 536/23.1, 23.5, 24.5, 24.31

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, DIALOG, MEDLINE, BIOSYS, JAPIO, EMBASE, DERWENT WPI.

search terms: fsh05, chromosome 18, bipolar, neuropsychiatric, treatment, hypomania, depression, gene expression, linkage, disorder, neurological, psychiatric, schizophrenia, activity, detect, immunoassay, hybridization, hybridize, mutation, allele, allelic, disease association